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The large-conductance, voltage- and calcium-activated potassium channel 
(BKCa channel) is an important transmembrane ion channel involved in many 
physiological and pathophysiological processes. However, little is known about 
its atomic-level three-dimensional structure. The functional channel requires four 
alpha subunits assembled as a potassium pore and is typically associated with 
four beta subunits that regulate function in various ways depending on the 
isoform of the beta subunit is interacting with the channel. Currently, the only 
major high-resolution atomic structure available is of the cytosolic tail domain of 
the alpha subunit. In the absence of structural information, electrophysiology has 
allowed for extensive characterization of the channel’s role in physiological 
processes and advanced understanding of BKCa channel pharmacology including 
inhibition of BKCa by physiologically relevant concentrations of cholesterol and 
stimulation of BKCa by the related sterol, lithocholic acid. However, many 
questions still remain including how does cholesterol exert effects on the alpha 
subunit, what are the structures of the different beta subunits, and can 
therapeutic lead compounds be developed to selectively target BKCa beta 
subunits in a tissue specific manner. The difficulty of obtaining transmembrane 
protein structures has made characterization a major challenge. 
Herein, work is described where 1) the BKCa beta 1 subunit was 
successfully expressed and purified from E. coli for the first time with a yield of 
v 
approximately 32mg/L of bacterial growth and several assays were attempted to 
demonstrate protein functionality. However, functional assessment of purified 
protein has remained elusive due to the hydrophobic nature of known ligands. 
Additional effort is needed to establish ligand recognition using solution nuclear 
magnetic resonance spectroscopy. 2) Multiple generations of pharmacophore 
models have been developed to aid in virtual screening efforts to find therapeutic 
lead compounds targeting BKCa through the beta 1 subunit. Sixteen compounds 
have been selected from virtual screening of the PubChem database that can be 
tested in vitro for model validation. 3) Molecular dynamics simulations were 
utilized to study the underlying mechanism of the interaction between cholesterol 
and the BKCa alpha subunit cytosolic tail domain showing differential behavior of 
cholesterol in mutant and wild type simulations that agree with experimental data. 
vi 
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An Introduction to Experimental Techniques and the Large Conductance, 
Voltage- and Ca2+-Activated K+ Channel 
 
 
The large conductance, voltage- and Ca2+-activated K+ channel, also 
called BK, BKCa, MaxiK or Slo1 channel, is a voltage- and Ca2+-gated K+ ion 
channel that is ubiquitously expressed and localized in mammalian cell 
membranes.1 It is a member of the six transmembrane domain (TM6) ion 
channel super family and the Ca2+-activated K+ channel family, also called the 
KCa family. Although all members of the KCa family (BKCa, IKCa and SKCa) are 
involved in repolarization of cell membrane potential, BKCa plays a role in several 
important physiological events including neuronal hyperpolarization, 
neurotransmission, hormonal secretion, and regulation of tone in both vascular 
and non-vascular smooth muscle.2,3 All members of the KCa family share 
structural features including their voltage-sensing domains, which open the K+ 
pore in response to depolarization of the cell membrane, and pore-forming 
transmembrane domains (to be discussed later). Yet they vary in, and are 
classified by, their conductance. Of all known Ca2+-gated K+ channels family 
members, the BKCa channel, which stands for big conductance of K+, has the 
largest unitary conductance at 100-300 picoSiemens (pS)4 while other members, 
including the intermediate conductance (IKCa) and small conductance (SKCa) 
channels, have conductances of 25-100 pS5,6 and 2-25 pS7 respectively. While 
the effect of Ca2+ concentration on cellular K+ permeability was first reported in 
19585 and a change in ionic current due to increased intracellular calcium was 
2 
demonstrated in 1970,8 it was not until 19814 that the BKCa channel was 
identified as the first member of the KCa family partially responsible for the 
observed effect that increased intracellular Ca2+ has on K+ permeability.  
1.1 Structure and Function of the α and β Subunits 
Functional BKCa channels result from association of four identical slo1 
proteins, also called α subunits9, which were first characterized from Drosophila 
by identifying conserved sequences between BKCa and the previously 
characterized Shaker voltage-gated potassium channel.10,11 Each α subunit is 
composed of seven transmembrane (TM) segments (Figure 1, labeled S0 
through S6), which form both the voltage-sensing domain and the pore-forming 
domain. The voltage-sensing machinery includes elements that span the S0 to 
S4 segments while the pore-forming domain is comprised of S5 and S612 (Figure 
1). Voltage sensing is primarily conferred by a series of charged residues on 
different segments in the voltage-sensing domain that will alter protein 
conformation in response to ion concentration changes in the intracellular or 
extracellular environment through charge repulsion; D153 and R167 on S2, D186 
on S3, and R213 on S4.13 The S0 segment and the long cytosolic tail domain 
(CTD) are found in BKCa, but not in purely voltage-gated TM6 potassium 




Figure 1. Cartoon Diagram of BKCa α and β Subunits 
A) The pore-forming α subunit contains seven TM domains (S0-S6) and a long 
intracellular tail domain (CTD) where two Regulator of Conductance for K+ (RCK) 
domains are found. S0 (purple) is a primary element for interaction between α 
and β subunits. Structural elements from S0 to S4 (orange) participate in the 
voltage-sensing machinery while S5 and S6 (green) form the K+ pore. The β 
subunit (blue) consists of two TM domains with an extracellular loop connecting 
the TM domains and has short intracellular C- and N-termini. B) The functional 
channel is composed of four identical α subunits (colored red), which can operate 
alone or with four regulatory β subunits (colored blue). C) Top view of BKCa 
channel assembly. β subunits (blue) interface between two pore-forming α (red) 





The long CTD contains approximately 800 residues and includes two 
regulator of conductance for K+ domains (RCK1 and RCK2).17 These domains 
include two high-affinity Ca2+ binding sites that embolden the channel to open at 
a lower membrane potential threshold in response to increase in Ca2+ within the 
intracellular physiological range (hundreds of nanomolar to tens of micromolar) in 
a concentration dependent manner (as Ca2+ concentrations increase, the voltage 
required to open the channel decreases).18 The proximal high affinity site is 
located in RCK1 and involves residues D362 and D36719 and the distal is in 
RCK2 and includes the so-called “Ca2+-bowl”, a penta-aspartate sequence.20 
In smooth muscle, BKCa channels induce currents that result from channel 
activation following the release of Ca2+ from intracellular Ca2+ stores or influx of 
Ca2+ through Cav channels after initial membrane depolarization. Intracellular 
Ca2+ in turn binds to and opens BKCa channels leading to hyperpolarization, or a 
negative electrical potential shift, of the cell membrane by allowing K+ to flow 
down its electrochemical gradient and out of the cell.21-24 Hyperpolarization of the 
membrane then prevent further Ca2+ influx into the cell by deactivating voltage-
dependent Ca2+ channels, which remain closed at the negative resting potential 
of approximately -70 mV, effectively terminating the influx of Ca2+ and stopping 
muscle contraction.25,26 
While differential phenotypical channel gating and kinetics can be 
achieved through alternative splicing of the slo1 gene to produce different 
isoforms of the α subunit,27-29 accessory β subunits offer alternative means of 
channel modulation. Expression of the four known accessory β subunits (β1-β4) is 
5 
highly tissue-specific, and their presence in the BKCa channel complex provides a 
tissue-specific phenotype (see below) that allows the BKCa channel to serve cell 
physiology in a tissue-specific manner.30-32 The β subunits are smaller proteins 
composed of two putative TM segments, intracellular N- and C-termini, and an 
extracellular loop connecting TM1 and TM2 that is 116-128 amino acids in 
length30,33 (Figure 1). Four β subunits assemble with the tetrameric α channel to 
form a hetero-octameric quaternary structure.34 Crosslinking experiments 
indicate that TM1 of the β subunit is positioned near S1 of one α subunit and 
TM2 is positioned near S0 in another α subunit of the assembled channel.35 A 
recent mutagenesis study suggests that β1 and β2 subunits may increase 
channel opening at lower voltages as [Ca2+] increases by disrupting the disulfide 
bonds formed at interface between the voltage-sensing domain and the 
intracellular C-terminal domain and also decrease voltage sensitivity by 
preventing ionic interactions with R213 in the voltage-sensing domain.36 
Each subunit has distinctly different effects on channel behavior. β1 has 
the largest effect on voltage-dependent activation, both reducing the voltage 
sensitivity by shifting the voltage required to open 50% of channels (V1/2) in patch 
clamp experiments more negative37,38 and increasing Ca2+ sensitivity by reducing 
the voltage required to open the channel as [Ca2+] was increased in patch clamp 
experiments.39 β1 is expressed primarily in smooth muscle and the kidneys.40-42 
The β2 subunit does not shift on voltage-dependent opening and closing of the 
channel,37,38 but makes the channel more sensitive to Ca2+ concentration as 
evidenced by the decreased voltage required to open the channel as [Ca2+] 
6 
increases,43 although not to the same extent as β1, and can decrease channel 
open probability channel conductance through an intracellular N-terminal “ball” 
peptide.44 β2 is expressed primarily in the brain.44 The two subunits appear to 
confer Ca2+ sensitivity in different ways as mutations in the voltage-sensing 
domain that reduce the voltage sensitivity modulation by β1 had no effect on 
modulation by β2.45 The β3 subunit, which is the least well studied, also 
inactivates the channel through an N-terminal peptide46, but not to the same 
extent as β2.47 This “incomplete” inactivation could be due to the lower affinity of 
BKCa α for β3 when compared to β2, as evidenced by faster dissociation rates for 
β3.48 β3 is expressed in many tissues including the testis49 and the pancreas.50 
The β4 subunit has been shown to slow gating kinetics while also increasing Ca2+ 
sensitivity,31 and is expressed in neuronal tissues.49 Finally, several new 
modulatory proteins, called leucine-rich repeat-containing protein, or “BKCa γ 
subunits,” have been shown shift the voltage dependence of the channel to -140 
mV, representing the largest known modulation of the voltage dependence of 
BKCa α.51,52 However, little else is known about these accessory proteins at this 
time.  
While no complete crystal structure of the α subunit has been published to 
date, the structure of the intracellular gating ring (shown as RCK1 and RCK2 in 
Figure 1 and also called the cytosolic tail domain or CTD) of the BKCa channel α 
subunit has been determined in both the open and closed “states” by X-ray 
crystallography.17,53 The transmembrane segments, however, remain largely 
uncharacterized. Recently, the intracellular loop between S0 and S1 was 
7 
characterized by NMR and shown to contain two amphipathic helices, which are 
expected considering their proximity to the cell membrane.54 In addition, a cryo-
electron microscopy structure of the whole channel has been reported showing a 
globular structure similar, in many ways, to K+ channels of known structure.55 
Even less high-resolution structural data are available for the β subunits: 
only the structure of the N-terminal peptide of β2 determined by NMR has been 
reported to date.56 The lack of atomic resolution structural data leaves a 
tremendous gap in our understanding of both the structure and function of a 
channel that is involved in critical aspects of mammalian physiology, as 
mentioned in section 1.3. Thus, further structural studies would greatly enhance 
our understanding of BKCa channel activation and deactivation through 
examination of structures in both states, modulation by Ca2+ and voltage by 
identifying the structural features and changes involved, interactions with 
different β subunits, and identification of binding and interaction sites with 
ligands. Expanding understanding of the topics could lead to the development of 
novel therapeutic lead compounds. For a recent and extensive review on BKCa 
structure, function, and physiology, which will be discussed to an extent in the 
coming sections, see Contreras, 201357 or Dopico et al. 2012.58 
1.2 The β1 Subunit 
The β1 subunit, which is the focus of Chapter 3 and Chapter 4 of this 
dissertation, is the best studied of the β subunits. When the α subunits are 
expressed alone, the channel has low sensitivity to Ca2+ and shows activation 
only at highly positive membrane potentials of +40 mV59 like those seen after 
membrane depolarization as a result of action potentials in neurons and muscles. 
8 
In the presence of the β1 subunit, however, the channel exhibits increased Ca2+ 
and decreased voltage sensitivity.60,61 In addition, both channel opening and 
closing kinetics are slowed in patch clamp recordings.62 Modulation of voltage 
sensitivity and gating of BKCa by β1 is known to involve four residues in the 
extracellular loop of β1 (Y74, S104, Y105, I106), which have been identified by 
alanine-scanning mutagenesis63 in addition to the possible disruption of α subunit 
domains previously mentioned.36 The CTD was also identified as essential for β1 
modulation of the channel as CTD truncated channels are not modulated by β1.64 
However, the interaction and interfacing between α and β subunits is not 
understood. 
The β1 subunit has a well-characterized cholane steroid-recognition site,65 
which will be discussed in more detail in section 1.4 and is not found in any other 
β subunits, providing this subunit with distinct pharmacological properties. 
Moreover, the tissue-specific expression of β1 in smooth muscle40 and the role β1 
plays in vasoregulation by inducing vasodilation41 makes it an attractive target for 
structural characterization. This would provide understanding of the binding and 
interaction sites for in the β1 subunit and could lead to development of agents to 
counteract pathophysiologies, discussed in the next section, by targeting β1-
containing BKCa channels (e.g., new vasodilators or smooth muscle relaxants).  
1.3 Pathophysiological Relevance of the Large-Conductance Ca2+-Activated 
K+ Channel 
The BKCa channel plays a role in membrane polarization events through 
Ca2+ and voltage gating, or the opening and closing of the K+ pore,66 which can 
act independently. As a result, this channel is a critical player in many 
9 
physiological processes including insulin secretion,67 smooth muscle dilation,30 
neuronal transmission,68,69 arterial constriction and dilation,25,70 cochlear hair cell 
tuning,71 detection of O2 concentration in the carotid body,72 release of glutamate 
from nerve terminals,73 capacitation of human spermatozoa,74 apoptosis75 and 
cell viability,76 K+ secretion from the kidneys,77 and signaling by luteinizing 
hormone and human chorionic gonadotropin in testicular Leydig cells.78 As 
mentioned previously, tissue specific channel behavior is controlled through slo1 
gene splicing and differential, tissue-specific expression of β subunit types 
allowing the channel to be involved in so many different physiological processes.  
Mutations and alterations in BKCa expression can result in pathological 
conditions. In particular, several neurological conditions appear to involve the 
BKCa channel. For example, one study showed that mRNA levels of BKCa slo1 
transcripts are up to 40% lower in the prefrontal cortex of people diagnosed with 
schizophrenia.79 Another study showed that haploinsufficiency (having only one 
copy of a gene) and a mutation in a highly conserved region of the α subunit of 
BKCa cause the decreased channel activity found in people with autism and 
mental retardation.80 It was postulated that the mutation and decrease in channel 
activity, which reduce neuronal excitability and synaptic transmissions, 
contributed to the pathophysiology of these disorders.80 Furthermore, deletion of 
A750 in the β3 subunit gene, which causes early termination of the protein during 
translation, is correlated to people with idiopathic generalized epilepsy.81 The 
D434G mutation in the α subunit has also been linked to epilepsy and a 
movement disorder.82 This may be caused by the increased Ca2+ sensitivity and 
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open time characteristic of the mutant channel,82-85 which are due to increased 
flexibility in the intracellular portions of the protein.86,87 Additionally, BKCa β4 
knockout mice show epileptic repetitive action potentials in 
electroencephalograms, but do not exhibit the entire epileptic phenotype.88 It is 
hypothesized that β4 serves to reduce the contribution of the BKCa channels to 
membrane repolarization.88 
Several pathologies related to smooth muscle function are also linked to 
the BKCa channel. Genetic knockout41 or suppression89 of the β1 gene in mice 
produces animals with systemic hypertension. This is caused by the loss of the 
modulatory effect of β1 on the channel-forming α proteins; this loss makes the 
channel complex insensitive to ryanodine receptor-mediated Ca2+ “sparks” and 
prevents vasodilation,90,91 but may also cause the loss of ability to secrete K+ 
from the kidneys.92 Conversely, a gain-of-function mutation in human β1 showed 
protection against diastolic hypertension in a population epidemiology study.93 
For a review on the role BKCa plays in the regulation of vascular tone, see 
Ledoux 2006.94 Erectile dysfunction95 and hypercontractility of corpus 
cavernosum smooth muscle96 have also been reported in Slo1 genetic knockout 
mice. Slo1 knockout mice also displayed overactive bladder and incontinence 
caused by increased bladder smooth muscle contractility from the lack of current 
produced by BKCa.97,98 Furthermore, a recent study evaluated expression levels 
of α and β subunits in human urinary bladder and found decreased expression of 
both subunits in smooth muscle of people with overactive bladder.99 In the lungs, 
the role of BKCa in bronchial smooth muscle is less well understood.  However, β1 
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subunit knockout mice showed increased tracheal contractility compared to 
controls,100 as normal BKCa works by opposing the effects of cholinergic M2 
receptor activity in tracheal smooth muscle cells.101 Additionally, activated BKCa 
channels in lung endothelial cells have been shown to induce vasodilation.102 
Finally, BKCa α and β subunits play roles in kidney function, diabetes, and 
obesity. The α and all four β subunits are expressed in the nephrons103 with α 
subunit expression being regulated by aldosterone levels and urine pH.104 In the 
kidneys, BKCa serves to secrete K+ from the distal nephron.77 Diets high in K+ 
have been shown to increase expression of BKCa α in the kidneys, while low K+ 
diets decreased expression in immunohistochemical staining105 and, as 
mentioned previously, the systemic hypertension reported in β1 knockout mice 
might be a result of increased aldosterone levels and decreased K+ secretion 
efficiency.92 Increases in glomerular filtration rate and Na+ secretion, as well as 
decreases in K+ secretion, were also observed in β1 knockout mice.42 For an 
extensive review of the role BKCa plays in the kidney see Pluznick et al.106 
BKCa dysfunction has also been linked to several pathophysiological 
conditions manifested in diabetes. While previous studies showed that overactive 
bladder was linked to decreased expression levels of α and β1 subunits,99 
increased expression of α and decreased expression of β1 has been observed in 
diabetic rat bladder smooth muscle, also leading to overactive bladder.107 
Recently, Yi et al. hypothesized a role for the protein MuRF1, a protein known to 
be involved in heart disease, in the proteolytic breakdown of β1 and eventual 
diabetic vasculopathy, after observing decreased β1 expression when MuRF1 
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expression increased in diabetic mouse vascular smooth muscle.108 When BKCa 
α was blocked using iberiotoxin, which is discussed in section 1.4, a 70% 
increase in insulin secretion was observed in human pancreatic β islet cells67.  In 
addition, increase in insulin was shown to increase BKCa α expression109 
suggesting a role for BKCa in regulating insulin secretion.  
Finally, the molecular mechanisms by which obesity affects BKCa function 
are beginning to emerge. Studies on Zucker diabetic fatty rats, an obese diabetic 
rat model organism, have shown reduced activation of BKCa compared to non-
fatty rats110 and decreased activation of BKCa by arachidonic acid111 in smooth 
muscle cells isolated from the arteries of Zucker diabetic fatty rats. Also, β1 
expression in obese rats was decreased in cremaster muscle arterioles, but 
increased in middle-cerebral arteries with no change in α subunit expression 
compared to non-obese controls.112 
1.4 Channel Pharmacology and Therapeutic Potential 
With the physiological significance of the BKCa channel established and 
the channel involvement in many pathological conditions coming to light, the 
value of the BKCa channel α and β subunits as a pharmacological target has 
received increasing attention. Many compounds have been discovered, which 
are discussed in more detail in section 1.4, that either activate or block channel 
activity. However, there have been no successful clinical trials on BKCa channel α 
or β subunit modulators so far. The lack of therapeutic agents targeting BKCa 
could be due to an absence of specificity or potency of compounds currently 
available. Most significantly, the scarcity of high resolution structural data 
contributes to poorly characterized binding sites for most ligands, impeding 
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efforts to develop alternatives ligands with improved potency and specificity. This 
section will focus on the compounds and peptides that target BKCa α or β 
subunits and what is known, if anything, about their binding sites and effects on 
channel behavior. 
There are two peptide toxins known to target BKCa α subunits: 
charybdotoxin113 and iberiotoxin.114 They are both capable of inhibiting channel 
function at nanomolar concentrations by binding to the channel extracellular 
surface.113 Moreover, a solution structure for unbound charybdotoxin has been 
reported.115 While channels coexpressed with β1 have the same affinity for 
charybdotoxin as α alone,44 channels containing β2 or β3 show a 30-fold 
decrease in affinity,44,47 while channels containing β4 have a 1,000-fold decrease 
in affinity.116 The difference in affinity in β4 subunit containing channels is derived 
from the presence of several basic residues in the extracellular loop that prevent 
binding of charybdotoxin.117 While charybdotoxin binding affinity for α+β1 
channels remains the same, β1 causes a 7-fold decrease in the dissociation rate 
constant (Kd),118 an effect that seems to be associated with four residues in the 
β1 extracellular loop.119 Iberiotoxin differs from charybdotoxin in that it is specific 
for BKCa channel α subunits and has a Kd of 1 nm, 10 times lower than that of 
charybdotoxin, although both toxins appear to work by a similar mechanism that 
involves blocking the K+ pore.114 
Several small molecule BKCa channel modulators have also been 
reported. A series of small molecules derived from fungal toxins were shown to 
selectively block BKCa in bovine aortic smooth muscle cells.120 Conversely, the 
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benzimidazolone series of compounds provided several potent channel openers 
including NS 004, NS 1609, and NS 1619 (Figure 2). NS 1619 was the first of 
these compounds found to evoke hyperpolarization of aortic smooth muscle 
cells121 and rat neurons via activation of BKCa channels.122 NS 1609 was later 
shown to open BKCa channels leading to hyperpolarization through channel 
opening in rat and human bladder smooth muscle cells in lower 
concentrations.123 However, NS 1609 blocks channel opening when higher 
concentrations were applied in guinea pig bladder smooth muscle cells while NS 
004 did not.124,125 Recently, the mechanism of this class of channel openers was 
shown to require the linker between S6 and RCK1 of the α subunit, suggesting 
they elicit effects through the CTD.126 Additionally, inhalation of NS 1619 was 
shown to reduce blood pressure in the right ventricle and improve blood 
oxygenation in a rat model.127 However, Bristol Meyers Squibb (BMS) 204352 
(Figure 2), a compound developed from the original benzimidazolone series, 
failed to show decreased neuronal cell death in clinical trails for the treatment of 
acute ischemic stroke,128 which involves large influxes of Ca2+ leading to 
neuronal cell death, although it was shown to be a potent and selective α subunit 
channel opener.129 Interestingly, NS 1619 is the only one in this series of 
compounds that does not effect other types of ion channels.121 Although this 
series of compounds has seen some exploration for therapeutic development, 
the lack of specificity for BKCa channels and a lack of tissue specificity due to 









Bile acids (Figure 3) have also been shown to be micromolar activators of 
BKCa channels.130 The cis stereochemistry of the A-B ring junction in the bile acid 
steroid backbone, a carboxylate functional group on the lateral chain, and a 
single hydroxyl with R stereochemistry on carbon 3 of the A ring were all shown 
to be important structural features required for channel activation.130 It was later 
shown that the bile acids required the β1 subunit for activation131 with a putative 
binding site in the second transmembrane domain.132 Moreover, lithocholic acid, 
the most potent bile acid activator of BKCa channels, had no effect on channels 
coexpressed with β2, β3, and β4.133 Later, the bile acid interaction site was shown 
to involve T169 in TM2 of β165 and further structure activity relationship (SAR) 
studies refined the understanding of bile acid structural requirements.134 
However, these compounds are not ideal therapeutics for chronic disease 
treatment because of their steroid backbone, which makes them potential ligands 
of cytosolic and nuclear steroid receptors and thus, facilitates their wide 
involvement in several physiological processes and transcriptional regulation. For 
a review on bile acid biogenesis and function see Chiang 2013.135 Finally, 
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cholesterol has been shown in multiple studies to decrease channel opening 
events.136,137 The binding site of cholesterol was identified by our experimental 
collaborators at the University of Tennessee Health Science Center as a series 
of cholesterol amino acid consensus (CRAC) motifs in the CTD of the α 
subunit.137 CRAC motifs have previously been shown to effect other membrane 
protein ion channels,138 but the mechanism of the interaction between the amino 
acids in the motif and cholesterol are not known. Chapter 2 outlines 
computational experiments used to better understand the interaction between 








There are two natural compounds obtained from herbs that activate BKCa 
channels. The first, dehydrosoyasaponin-1 (DHS-1, Figure 4), was reported to 
activate BKCa α subunits in 1993139 and later shown to require the β1 subunit to 
modulate the channel.39 When applied to the inner artificial membrane leaflet, the 
compound reversibly increases the probability of the channel being open in patch 
17 
clamp experiments,140 but due to the large polar sugar moiety preventing the 
compound from partitioning through the membrane, this compound does not 
produce an effect when applied to the outer membrane. Interestingly, a database 
search based on a pharmacophore derived from bile acids returned a related 
compound, 3-hydroxyolean-12-en-30-oic acid (3-HENA, Figure 4), that was 
shown to activate BKCa through the β1 cholane steroid-recognition site with a 
greater increase in channel open probability and duration of effect than lithocholic 
acid.141 Three-HENA was able to induce cerebrovascular dilation in vitro and in 
vivo through BKCa channels containing α and β1 subunits, which underscores 
drug access to the channel from circulation and the extracellular side of the cell 
membrane.141 While both DHS-1 and 3-HENA are triterpenoid compounds, 3-
HENA lacks the sugar moiety thus allowing it to partition through membranes 
more readily than DHS-1. However, the hydrophobic nature of the compound 
would also present challenges in bioavailability if used as an oral therapeutic 
since it would not readily leave cell membranes and therefore would not reach 
the circulatory system in sufficient quantities if given orally. The other naturally 
derived compound, called MaxiKdiol (Figure 4), activates α subunits with or 
without β subunits present.142 
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Figure 4. Plant Derived Compounds that Activate BKCa 
DHS-1 and MaxiKdiol are both derived from herbs. DHS-1 and 3-HENA are both 
triterpenoid compounds, but 3-HENA was chemically modified after purification 




An interesting group of compounds that modulate BKCa are the estrogens, 
specifically estradiol, and estrogen mimetic agents (Figure 5) as well as anti-
estrogens. Seventeen-β estradiol was first shown to activate BKCa, as well as 
voltage-gated Ca2+ channels, from the extracellular side of the membrane by 
Valverde et al143 and was later shown to alter redox function in macrophages by 
activating BKCa.144 Later, the N-terminal residues of the α subunit were shown to 
be necessary for the effect of estradiol on β1 subunits.15 Tamoxifen (Figure 5), an 
estrogenic compound, also induced activation of BKCa but required β1 subunits;145 
both estrogen and tamoxifen were ineffective at inducing vasodilation in β1 
knockout mouse smooth muscle cells.146 However, it has also been shown that 
an α subunit is sufficient for channel sensitivity to estradiol, while co-expression 
with the β1 subunit increases the apparent binding affinity of estradiol.147 The 
anti-estrogen compound fulvestrant148 and bisphenol A, a compound developed 
as an estrogen mimetic that is now used in plastics,149 have been shown to 
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produce the same effect on BKCa as estrogen. However, no interaction site has 
been established for estrogen or any of the estrogen mimetic compounds 
mentioned here. Without an interaction site and due to the many biological 
targets of estrogen hormones, pursuing therapeutics that mimic estrogen could 
have a wide and undesirable side effect profile. 
 
 




Although there are many modulators of BKCa, including small molecules 
and peptides, very few of these compounds have known binding or interaction 
sites. Furthermore, only a small number of compounds (bile acids, and 3-HENA) 
are known to exert their effects on BKCa through a defined interaction site on the 
β1 subunit. With a lack of defined binding sites, design and optimization of novel 
activators poses a significant challenge. Information about existing ligands can 
be useful for database mining, similarity searching, and pharmacophore 
searching, but structural data of the biological target would greatly enhance the 
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understanding of and design of potential new therapeutics. For an extensive 
review of BKCa channel pharmacology see Nardi and Olesen 2008.150  
1.5 Molecular Dynamics to Study Biomolecular Interactions 
While experimental techniques like alanine scanning mutagenesis can be 
useful for determining protein-ligand binding sites, these studies do not reveal the 
dynamic interactions between the protein and ligand. Conversely, molecular 
dynamics cannot be used to easily identify ligand binding sites due to limitations 
with computational resources and the time required for simulations. The 
combined application of experimental and computational approaches can be 
used to gain insight into protein-ligand interactions. Molecular dynamics (MD) 
simulations have been used to study proteins in a dynamic environment versus 
the static picture provided by X-ray crystal structures or solution and solid state 
NMR structures. Mathematical models of the dynamic multi-conformational 
properties of proteins first appeared in 1985151 and have been reviewed 
extensively.152,153 Although this is not an exhaustive list, MD simulations have 
been used to demonstrate how the dynamic structure of the protein can control 
ligand diffusion into active sites or binding sites154,155 and modulate receptor 
affinity,156 to understand the effects of protein mutagenesis on ligand 
interaction,137,157 and even to elucidate the inhibition of influenza by mammalian 
proteins using large-scale simulations.158 These different studies exemplify the 
vast applicability of MD in understanding complex biological macromolecules, 
their dynamic fluctuations, and their interactions with ligands or other 
macromolecules, but an understanding of how MD works and the limitations of 
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the simulations is required to appreciate, understand, and correctly implement 
the technique. 
Although the concept of molecular dynamics was developed in 1959159 for 
use in theoretical physics, it has expanded, due to the advancement of 
microprocessors, to study large complex systems of biomolecules. In their most 
basic form, MD simulations use the Hamiltonian operator of every atom in the 
system treated classically and solves for the forces acting on the atom by 
integrating Newton’s equations of motion.160 For every time step in a simulation, 
the equations of motion are integrated and new velocities and positions for each 
atom are acquired.161 Every MD program must contain a model for interaction of 
all atoms or molecules, an integrator to solve atomic positions and velocities over 
the time steps of the simulation, and a statistical ensemble that controls the 
thermodynamic properties of the simulation, including the number of particles in 
the system, temperature, pressure, and volume.161 Due to the complexity of 
these calculations, the size of a system simulated and the length of time 
simulated are inherently limited. Newer parallel processing technologies, like 
NVIDIA CUDA, have greatly expanded the feasible number of atoms in a 
simulation and the length of the simulation, while also reducing the number of 
computing hours needed to complete the simulation. This brings simulations 
within reach that were previously not possible because of scale. The picosecond 
to microsecond time scale now possible with MD allows for the observation of 
molecular collisions and bond rotation and vibration, but cannot simulate the 
movement of electrons due to the use of classical mechanics.161 The use of 
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classical mechanics is a limitation that prevents the simulation of bond forming or 
bond breaking using traditional MD, but may be overcome using hybrid quantum 
mechanics/molecular mechanics methods. 
A major part of any MD simulation is the use of a force field to 
parameterize the molecules in the system. The force field in any simulation has 
an impact on the accuracy of the simulations performed, so care must be taken 
when choosing a force field to select one with appropriate parameters for the 
system being studied. Force fields must contain potential energy parameters for 
van der Waals interactions, bond stretching and bending, and torsional angles for 
all atoms and bond types in the system.161 These parameters must be fitted to 
reproduce empirical or ab initio calculation results. Additionally, both short- and 
long-range interactions must be accounted for and are typically treated 
separately. In AMBER 10,162 the software package used for simulations in 
Chapter 2, short-range interactions are approximated using a Lennard-Jones (LJ) 
potential163 and long-range interactions are approximated using the Particle 
Mesh Ewald (PME)164 technique, while the ff99SB force field165 uses an 
empirically derived potential. The PME technique has been shown to overcome 
shortcomings of other long-range approximation methods to reach agreement 
with experimental results166 and the LJ potential is implemented because of its 
mathematical simplicity and accuracy in approximations.161 
In conclusion, the use of molecular dynamics to explore protein-ligand 
interactions is a valuable tool to explain experimentally obtained results. While 
there are limitations on the applicability and what non-bonded interactions can be 
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accounted for because of approximations used to overcome computational limits, 
proper knowledge of MD and those limitations can yield high-value data to 
explain molecular behavior. For an extensive explanations of all equations, 
potentials, integrators, ensembles, and parallelization methods see Sutmann.161 
1.6 Ligand-Based Pharmacophore Modeling for Therapeutic Lead 
Compound Discovery 
Although it has been used in many ways and to mean many different 
things, the term pharmacophore is defined by the International Union of Pure and 
Applied Chemistry as “the ensemble of steric and electronic features that is 
necessary to ensure the optimal supramolecular interactions with a specific 
biological target structure and to trigger (or to block) its biological response” with 
pharmacophore descriptors being the points that define a pharmacophore.167 
While three dimensional (3D) pharmacophores were described before computers 
were used for 3D modeling,168 the first semi-automated pharmacophore modeling 
was described by Mayer et al in 1987.169 After that, a new era of computer aided 
drug design (CADD) made building models and searching molecular 
conformational databases feasible. Now, many programs exist to develop 
pharmacophore models using increasingly sophisticated algorithms that allow for 
the generation and testing of models. Models can be developed based on the 
structure of known ligands for a particular target, called “ligand-based modeling,” 
or can be generated from a known protein target structure, called “structure-
based modeling”. With very little structural information available for BKCa, a lack 
of well-characterized binding sites, and no structural data available for the β1 
subunit, the pharmacophore model discussed in Chapter 3 was developed using 
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a ligand-based method. Models of both types can be assessed for quality using 
the Güner and Henry method,170 which involves testing the predictive value of 
models against a set of compounds with known activity at the target protein. 
Validated models can then be used for database searching to find novel 
compounds that can be screened against the target protein in vitro. For an 
extensive review of the current state of pharmacophore modeling and future 
challenges see Yang 2010,171 Wolber 2008,172 or Langer 2006.173  
Since structural data is not currently available for the β1 subunit, but a 
cholane steroid-recognition site has been established, Chapter 3 of this 
dissertation describes the advancements in developing a ligand-based 
pharmacophore model for this interaction site. By utilizing the insight gained from 
previous structure activity relationship studies, models were developed that allow 
for rapid screening of available conformational databases to find compounds that 
can interact with the cholane steroid site in β1. With an end goal of discovering 
non-steroidal compounds that could be used to treat chronic conditions such as 
hypertension, the development of models for this interaction site make this goal 
attainable, although experimental validation of models is still needed. 
1.7 Transmembrane Protein Expression and Purification 
Transmembrane (TM) proteins represent a vast number of proteins 
encoded by the human genome with 37% of all open reading frames encoding 
proteins with at least one TM segment.174 Examples of transmembrane proteins 
are protein receptors that bind ligands on the outside of the cell and transmit a 
signal inside the cell, like G-protein coupled receptors, and transporter proteins 
that move molecules, ions, or peptides into or out of the cell, like the BKCa 
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channel. While TM proteins play a significant role in maintaining cellular 
homeostasis and receiving extracellular signals to coordinate cellular functions 
that make multi-cellular organisms possible, very few atomic resolution structures 
of TM proteins exist. Although the first atomic resolution membrane protein 
structure was published in 1985,175 only 464 (http://blanco.biomol.uci.edu -
/mpstruc/) of the 99,122 structures deposited in the Protein Data Bank176 (both 
websites were accessed April 5th, 2014) are unique membrane protein structures, 
which demonstrates the difficulty of membrane protein structural characterization. 
The deficit of structural data about transmembrane proteins combined with the 
physiological importance of the BKCa channel and the tissue specific expression 
of the β1 subunit outlined in section 1.3, underscores the desire to pursue 
structural characterization of the β1 subunit. While pieces of the α subunit 
structure and small fragments of some β subunits have been reported (see 
section 1.1), neither a complete structure of the channel nor any of the β subunits 
has yet to be reported.  
The reason for the relatively small number of available structures stems 
from the difficulty of maintaining a membrane-like environment and preventing 
amorphous protein aggregation from large spans of non-polar amino acids.177 In 
living cells, this process is handled by translocon cellular machinery that traffics 
membrane proteins from the cytosol where they are produced to the cell 
membrane,178 but after expression of a target protein in a host organism the 
protein must be extracted, purified, and stabilized for structural studies outside of 
the native cell membrane environment. While different systems have been 
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employed, which will be discussed in more detail in Chapter 4, there is currently 
no way to determine which system will work with a particular protein target, 
making membrane protein purification and stabilization a laborious process. 
Additionally, Escherichia coli, the host organism chosen for protein expression in 
Chapter 4, presents more challenges when expressing eukaryotic membrane 
proteins with prokaryotic cellular machinery, including inclusion body formation 
and lacking eukaryotic mechanisms for post-translational modification of proteins.  
Membrane proteins are divided into the β barrel class and the α helical 
class179 with the BKCa channel belonging to the latter. While many β barrel 
membrane proteins have been successfully denatured and refolded from 
inclusion bodies, it is more difficult with α helical proteins. In bacteria, the 
formation of inclusion bodies is caused by many factors, but the biggest 
contributors are the stress response from the cell and overwhelming the 
translocon machinery leading to truncated or misfolded proteins aggregated in 
the cytoplasm.180,181 Overcoming these problems has been achieved using fusion 
proteins that enhance solubility or target the protein for membrane insertion, 
weaker T7 promoters for expression by T7 RNA polymerase that slow expression 
rates, and using various E. coli cell lines optimized to express toxic or membrane 
proteins.182 While some of these methods were utilized in this study, the lack of 
certain post-translational modifications utilized in eukaryotic cells that are not 
present in E. coli could result in problems with protein structure and function. 
Post-translation modifications, used in eukaryotic cells to direct proteins to 
their destination or assist in folding and structure, do not occur to the same 
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extent in E. coli. As a result of bacteria lacking asparagine-linked post-
translational modification, problems with expression of β1 in E. coli could arise 
from the presence of two N-linked glycosylation sites in the protein.183 Since 
glycosylation often plays a role in maintaining proper protein structure in 
eukaryotic cells,184 misfolded or non-native protein structure could result from 
using a bacterial expression system. Previous studies demonstrated that 
enzymatic deglycosylation of β1 has a significant impact on channel properties 
causing an increase in open probability and mean open time of channels in 
patch-clamp experiments.185 However, the modulatory role of β1 was not 
eliminated, suggesting that some structural features were retained in the non-
glycosylated protein. It is possible, however, that β1 would not fold to the proper 
functional form if the sugars had been absent during expression.  Because of 
this, expression in E. coli could lead to non-native folding and potential 
aggregation or, if a structure were obtained, a structure with altered modulatory 
function relative to wild type β1. However, any structural insights gained would 
greatly improve upon what is currently known.  
The goal of Chapter 4 was to express and purify β1 protein in quantities 
sufficient for structural characterization using solution nuclear magnetic 
resonance (NMR) spectroscopy. While the protein was successfully expressed 
and purified, assessing the functionality of the protein remains a challenge 
necessary to overcome to justify the time and expense of NMR experiments. 
Although functionality could not be demonstrated, successful expression and 




Evaluation of the Interactions of Cholesterol with the BKCa Channel 




Biological lipids are involved in many physiologically important roles 
including the formation of cell membranes, cell signaling events, energy storage, 
and compartmentalization of cellular functions. Cholesterol (CLR) has been 
shown to play an important role in modulation of membrane protein functions 
through the cholesterol recognition amino acid consensus (CRAC) motif. This 
motif is loosely defined by the amino acid sequence L/V - X1-5 - Y - X1-5 - R/K 
(where X is any amino acid and “/” means or).186 Furthermore, CLR has been 
shown to alter the activity of members of every ion channel family.138 The action 
of cholesterol on these ion channels has been proposed to rely on protein-CLR 
interaction, alterations of membrane properties that subsequently alter ion 
channel activity, or modification of protein-protein interactions by CLR.138 
The modulation of the BKCa channel by CLR was first shown in 1989 when 
the ionic current of the channel was shown to decrease in the presence of 
CLR.136 At the time, membrane fluidity was hypothesized to cause the decrease 
in current, but more recently the effect of CLR was shown to involve several 
CRAC domains in the cytosolic domain of the protein.187 In the α subunit, ten 
CRAC sequences were identified with CRAC4-10 in the CTD portion of the 
protein.187 The CTD CRAC sequences were shown to be responsible for the CLR 
sensitivity of the protein through mutagenesis studies187 and are discussed 
below. Additionally, experiments showed that the enantiomer of CLR does not 
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alter channel currents188,189 supporting that the sensitivity of BKCa to cholesterol 
is likely due to a stereospecific interaction with the protein and not a result of 
altered membrane dynamics. 
In experiments on BKCa CRAC domains performed by our collaborators at 
the University of Tennessee Health Science Center, several truncations were 
made to elucidate which CRAC motifs identified from the primary sequence 
contributed to CLR sensitivity, as well as several mutations within CRAC motifs 
to determine the role of different residues in CLR sensitivity. The first truncation 
was immediately after the S6 transmembrane segment (Figure 1) and resulted in 
a channel insensitive to CLR despite the channel remaining functionally active.137 
This indicates the CRAC motifs found in the transmembrane segments (CRAC 1-
3) were not sufficient for CLR sensitivity in BKCa α subunits.137 Additional 
truncations were made in the CTD portion of the protein after CRAC4, CRAC6, 
and CRAC8 to determine to contribution of the cytosolic CRAC motifs to CLR 
sensitivity. CLR sensitivity was successively decreased compared to wild type 
(WT) protein with truncations after CRAC6 and CRAC8.137 Truncation after 
CRAC4 produced a protein more sensitive to CLR than WT, although the reason 
for this could not be determined.137 
The increased CLR sensitivity of the protein truncated after CRAC4 led to 
mutagenesis studies of CRAC4 residues V444, Y450, and K453 to produce 
V444A, Y450F, and K453A mutants.137 The V444A mutation produced a protein 
that was resistant to CLR inhibition, but not completely insensitive.137 The Y450F 
and K453A mutations completely abolished CLR sensitivity, underscoring their 
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importance in CLR recognition in the CRAC4 motif.137 The results of the Y450F 
and K453A mutations drove the molecular dynamics simulations of CLR in this 
study. 
Initial molecular dynamics simulations spanning 5 ns of simulation time 
were performed to elucidate differences in CLR behavior between wild type (WT) 
BKCa CTD and the proteins truncated after CRAC4, as well as two mutants, 
Y450F and K453A, to mimic the mutants examined experimentally. These 
simulations showed differences in time spent by CLR on the CRAC domain in the 
various constructs,187 but were only 5 ns in length, so longer simulations were 
needed to fully discern patterns or differences in molecular behavior between 
constructs.  
2.2 Methods 
The computational methods described in sections 2.2.1and 2.2.2 were 
originally published in the Journal of Biological Chemistry. Singh, A. K.; McMillan, 
J.; Bukiya, A. N.; Burton, B.; Parrill, A. L.; Dopico, A. M. Multiple cholesterol 
recognition/interaction amino acid consensus (CRAC) motifs in the cytosolic C 
tail of the slo1 subunit determine cholesterol sensitivity of Ca2+- and voltage-
gated K+ (BK) channels. Journal of Biological Chemistry. 2012; 287:20509-21. © 
The American Society for Biochemistry and Molecular Biology. The methods 
presented are the same, but simulations were extended to 200 ns and 




2.2.1 Protein Structure Preparation 
To help elucidate the nature of the interactions between CLR and the BKCa 
α subunit, simulations of the full cytosolic tail domain (CTD, residues 331-1118) 
and the truncated CTD (residues 331-456; referred to as trCTD) polypeptides 
were compared with that of mutants Y450F and K453A (simulated as truncated 
proteins and referred to as Y450F or K453A). The starting structures of the 
channel protein were based on the crystallized portion of the BKCa CTD (Protein 
Data Bank176 entry 3NAF53). The crystallized sequence was aligned with its full 
sequence from the UniProt database190 (accession number Q12791), and 
Molecular Operating Environment (MOE 2010.10)191 software was used to create 
a three dimensional homology model for the missing loops from residues 617 to 
716, 726 to 742, and 893 to 930 in the PDB crystal structure. The model was 
geometry-optimized using ff99SB,165 a forcefield parameterized for proteins, to a 
root mean square gradient of 0.5 kcal/mol.Å . The truncated structures were 
made by removing all residues after Ile-456, which is consistent with the 
truncation made for patch clamp experiments on recombinant channel protein. 
Mutated structures for Y450F and K453A were based on the truncated structure 
and mutations were made in MOE 2010.10 before geometry optimization. The 
preparatory files for the CLR molecule were generated in antechamber192 using 
semiempirical AM1-BCC charges,162 which have been parameterized to 
reproduce HF/-31* RESP geometry and atom charges. Counterions were added 
via teLeap to neutralize the systems. A salt concentration of 53 mM was created 
using 50 K+ and 50 Cl- ions for CTD simulations and 20 K+ and 20 Cl- ions for the 
truncated CTD simulations. The systems were solvated with TIP3P water193 with 
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15.0 Å padding on each side in a periodic box. CLR was manually placed above 
the CRAC4 motif with the sterol methyl groups facing the motif and the CLR 
hydroxyl placed in the vicinity of Lys-453 with the CLR hydrophobic tail near Tyr-
450, as described in previous models.186,194 
2.2.2 Molecular Dynamics 
Atomistic molecular dynamics (MD) simulations were run using the 
AMBER 10 software package162 on intracellular portions of the BKCa channel α 
subunit CTD and interacting CLR using the ff99SB165 and gaff force fields,195 
which are optimized for proteins and organic molecules, respectively. Two 
rounds of minimizations were run: 1,000 steps (2 ns) with the protein and CLR 
fixed and 100,000 steps (200 ns) with the molecules unrestrained. A restrained 
warm-up MD was run using a time step of 2 fs at constant volume for 100 ps, 
with a restraint constant, or energy penalty for moving an atom, of 10.0 
kcal/mol.Å2, which is sufficient to prevent movement from the starting position 
during equilibration phases, on the protein and CLR molecules. During this 
simulation, the temperature was raised to 300 K using the Langevin thermostat 
with a collision frequency of 1.0 ps-1. Water and ion densities were equilibrated 
via a restrained NPT ensemble (fixed number of particles N, pressure P, and 
temperature T) MD simulations (p = 1.0 bar) for 2 ns, using the same restraint, 
thermostat, and collision settings as during the warm-up. After 2 ns, the restraint 
was lifted, and production runs were recorded, using a time step of 2 fs. All MD 
simulations used the SHAKE algorithm196,197 to constrain covalently bonded 
hydrogen atoms and the Particle Mesh Ewald method164 to calculate long range 
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electrostatic interactions, using a cut-off distance of 12.0 Å. Histidines were 
represented as HIE (neutral charge: Nε-H, Nδ). 
2.2.3 Molecular Dynamics Trajectory Analysis 
The 200 ns trajectories obtained for each construct were analyzed using 
PTRAJ and CPPTRAJ198 from AmberTools 13.199 Visualization of molecular 
dynamics trajectories was accomplished using VMD 1.9.1200 (http://www.ks.ui-
uc.edu/Research/vmd/). Images were rendered using the Tachyon ray tracing 
library201 with secondary structure predicted using STRIDE.202 Solvent exposed 
surface area calculations were completed using SURF203 implemented in VMD. 
2.3 Results and Discussion 
Table 1 provides the residue numbers in the full BKCa sequence along with 
their residue numbers in simulation files. The CRAC motifs will be referred to by 
their number or BKCa residue numbers in this dissertation unless specified 
otherwise. The corresponding residue numbers are provided for context along 
with the sequence for each CRAC motif. 
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Table 1. CRAC Motif Residue Numbers in Human BKCa Protein and 
Corresponding Values in Simulation Files 





CRAC4 444-453 114-123 VISIKNYHPK 
CRAC5 461-466 131-136 LQYHNK 
CRAC6 564-575 234-245 LMIAIEYKSANR 
CRAC7 605-613 275-283 VKRAFFYCK 
CRAC8 815-822/23 485-492/93 VGSIEYLK/R 
CRAC9 1048-1060 718-730 LGDGGCYGDLFCK 




2.3.1 Protein Stability During Simulations 
The RMSD of the four different constructs (CTD, trCTD, K453A, and 
Y450F) were calculated for each 200 ns simulation to determine if protein 
stability remained constant over time. For each construct, RMSD calculations 
were performed only on protein residues and did not include CLR. Figure 6 
shows the trCTD, and the two mutant simulations K453A and Y450F that were 
based on the trCTD construct, have stable RMSDs of 4-5 Å over the 200 ns 
simulation. The CTD construct had a less stable RMSD over time, but all four 
simulations remained 7-8 Å over 200 ns. Simulation 4 of the CTD construct 
reached an RMSD of 10 Å early in the simulation, which could be a problem with 
the overall stability of the protein. Calculations of per residue deviations were 
necessary to determine if the whole protein in the CTD simulation set was 
deviating or if there were sections of the protein that were causing the overall 
RMSD to remain higher than the trCTD and mutant simulations.  
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Figure 6. RMSD of Proteins in All Simulation Constructs 
All three constructs based on the truncated protein (trCTD, K453A, and Y450F) 
achieved a stable RMSD around 4-5 Å. CTD simulations had higher RMSDs 
around 7-8 Å in all four simulations. 
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To examine the CTD simulations further, the RMSD was calculated for 
each residue for each of the four simulations over 200 ns. The per residue RMSD 
values are plotted in Figure 7. Residue numbers in simulation constructs are 1-
787, but correspond to 331-1117 in the full protein sequence. Residues 287-387 
in Figure 7 show a high RMSD.  These residues in the simulation construct 
correspond to residues 617-717 in the full protein sequence, a portion of the 
protein following CRAC 7 and containing two of the amino acid segments missing 
in the crystal structure template, which were modeled using MOE as described in 
section 2.2.1. The second area in the simulation construct with abnormally high 
RMSD values  (residues 563-600) also corresponds to a missing loop in the 
crystal structure that was modeled by MOE; residues 563-600 fall midway 
between CRAC 8 and 9. Additionally, residues at the amine and carboxy 
terminus of the protein have high RMSD values, as is expected since these 
residues are not anchored and have random coil secondary structure. Since 
these areas have high RMSDs throughout the simulations, the total RMSD for all 
residues (Figure 6) in CTD simulations is higher than in the trCTD, K453A, and 
Y450F simulations that contain only residues 1-126, all of which were resolved in 




Figure 7. Average RMSD of Residues in CTD Simulations 
A) Residues 1-787 in simulation constructs correspond to residue 331-1117 in 
the protein sequence. High RMSD values were calculated for residues found in 
sections missing from the crystal structure and modeled using MOE prior to 
simulation. B) Protein shown as ribbon structure. Residues 287 to 387 shown in 
green ribbon and residues 563 to 600 shown in orange ribbon. All CRAC4 (red), 
CRAC5 (blue), CRAC6 (yellow), CRAC7 (magenta), CRAC8 (teal), CRAC9 






Figure 7B shows the high RMSD regions colored as a green (residues 287 
to 387) and an orange (residues 563 to 600) ribbon structure. Due to the limited 
secondary structure of the orange region and the fact that it does not closely 
associate with the remainder of the protein, this part of the protein is highly 
mobile during simulation. The green region also associates very little with other 
parts of the protein, but has some secondary structural ordering in helices. 
However, these highly mobile regions do not contain CRAC motif residues 
(Figure 7B CRAC residues shown as blue stick models) and should have no 
impact on CLR behavior in CTD simulations since major protein conformational 
changes are not observed on this time scale in MD simulations. Because the 
protein remains stable over simulation time for each construct, the movement of 
CLR in each simulation can be evaluated without changes in protein 
conformation being a factor contributing to differences. 
2.3.2 Cholesterol Interactions with CRAC Motifs 
To determine if CLR exhibits variable dynamics in different simulated 
constructs, interatomic interactions within 5 Å of the H9 hydrogen atom in CLR 
(Figure 8) and any atom in the residues of the CRAC motifs (Table 1) were 
calculated. This atom was chosen in CLR because of the central location in the 
steroid nucleus. These interactions were calculated for CRAC4 residues in 
trCTD, K453A and Y450F simulations and CRAC4-CRAC10 residues for CTD 
simulations. Due to the CRAC4 motif being split between spatially distinct helix 
and random coil sections of the protein crystal structure, the CRAC4 contacts 
were separately calculated for residues 444 to 449 and 450 to 453 (Figure 9) and 
plotted together as discussed below. The plot for each construct below shows the 
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total number of interatomic contacts for each frame of the simulation, which is 
equivalent to 1 ps of simulation time. 
 
 
Figure 8. Hydrogen Atom in Cholesterol Used to Calculate Interatomic 
Interactions with CRAC Motifs 







   
Figure 9. Residues of the CRAC4 Motif 
A) Front view of CRAC4 motif with residues 450 to 453 in random coil (teal) and 
residues 444 to 449 in the helix (magenta). B) Side view of residues in CRAC4 
motif. Not all residues are labeled in each image, but all residues are labeled in 















In trCTD simulations (Figure 10, Figure 11), the first and third simulations 
show CLR molecules remaining on or near CRAC4 residues 450 to 453 through 
145 ns of simulation time. In simulation 1, an overlap region from 120 ns to 150 
ns can be seen with interactions between CLR and both sets of CRAC4 residues, 
but only interactions with residues 444 to 449 occur after 150 ns. The CLR 
molecule in both simulations begins to transition from residues 450-453 to 
residues 444-449 after 120 ns in simulation 1 (Figure 11A) and after 160 ns in 
simulation 3 (Figure 11C). Simulation 2 shows different behavior for CLR 
compared to simulations 1 and 3. In the second simulation (Figure 11B), CLR 
starts on the CRAC4 motif and migrates away to another part of the protein not 
identified as a CLR recognition site and remains away from CRAC4 residues 
throughout simulation time, coming close enough to register a small number of 
interactions briefly around 170 ns. Additionally, the hydrogen bonds between the 
hydroxyl of CLR and the side chain of K453 are shown as green circles on each 
plot in Figure 10. In all three simulations, hydrogen bonds occur in high 
frequency during times where interatomic interactions are high (10 to 15 
interactions per frame) or immediately preceding high interaction periods. This 
indicates the hydrogen bond between K453 and CLR may be important in CLR 
recognition or keeping CLR in contact with CRAC residues and is discussed in 




Figure 10. trCTD Simulations Cholesterol and CRAC4 Interatomic Contacts 
Contacts less than 5 Å between CLR H9 atom and residues in CRAC4 shown as 
total number of contacts per frame (1ps) of each simulation. Green circles 





Figure 11. Positions of Cholesterol on CRAC4 Motif in trCTD Simulations 
CLR (stick models) coordinates in 200 ns simulations shown every 50 ns. Time 
steps shown are 0 ns (red), 50 ns (pink), 100 ns (white), 150 ns (purple), and 200 
ns (blue). Protein is shown as ribbon structure with CRAC4 residues as ball and 
stick models. A) Simulation 1 has CLR remain on the CRAC4 motif throughout 
the simulation. B) Simulation 2 shows CLR molecule starting on CRAC4 (red) 
and moving around the protein early in the simulation. C) Simulation 3 shows 
CLR remaining on CRAC4 throughout simulation time, but beginning to move 





For K453A mutant simulations, the CLR molecules migrate quickly from 
residues 450-453 to the spatially distinct residues 444-449 in a helical section of 
the protein (Figure 12). Simulation 2 shows 5-15 interatomic interactions with 
residues 444 to 449 after 100 ns, indicating close proximity to several of the 
residues. This was confirmed by examining the positions of CLR throughout 
simulation time, where Figure 13B shows CLR in close proximity to residues in 
the helical portion of CRAC4 in the 100 ns, 150 ns, and 200 ns snapshots 
(colored as white, purple, and blue, respectively). The third simulation shows 
CLR moving away from all CRAC4 residues around 40 ns and moving to a 
separate part of the protein, but returning to CRAC4 residues 444 to 449 in the 
last 50 ns of simulation. The variable behavior of CLR on K453A simulations 
compared to trCTD simulations, where CLR stays on residues 450 to 453 
through 150 ns of simulations 1 and 3, could be due to the K453A mutant lacking 
a side chain capable of hydrogen bonding with the hydroxyl of CLR. For 
comparison, the number of hydrogen bonds between the CLR hydroxyl and 




Figure 12. K453A Simulations Cholesterol and CRAC4 Interatomic Contacts 
Contacts less than 5 Å between CLR H9 atom and residues in CRAC4 shown as 




Figure 13. Positions of Cholesterol on CRAC4 Motif in K453A Simulations 
CLR (stick models) coordinates in 200 ns simulations shown every 50 ns. Time 
steps shown are 0 ns (red), 50 ns (pink), 100 ns (white), 150 ns (purple), and 200 
ns (blue). Protein is shown as ribbon structure with CRAC4 residues as ball and 
stick models. A) Simulation 1 has CLR move away from K453A early in 
simulation and remain near helical CRAC4 residues B) Simulation 2 shows a 
similar molecular behavior to simulation 1. C) Simulation 3 shows CLR move 





Y450F simulations (Figure 14) showed lower occurrence of 10-15 
interatomic interactions with CRAC4 residues 450 to 453 compared to trCTD 
simulations (Figure 10), which indicates fewer close associations with these 
residues during simulation time. However, the first and second simulations show 
sustained interatomic contacts of around 5 throughout simulation time, which 
corresponds to the location of CLR near Y450F shown in Figure 15 A and B. In 
both simulations, CLR migrates toward the mutated residue early in the 
simulations and in simulation 1 moves back toward K453 around 150 ns and 
shows a marked increase in hydrogen bonding (represented as green circles) 
before moving to the helical CRAC4 residues. Simulation 3 deviates from the 
behavior in the first and second simulations by moving quickly to the helical 
CRAC4 residues, but remaining far enough from the residues that 2 interatomic 
interactions are reported for most of the simulation with spikes of increased 
interaction throughout. The difference in CLR behavior in the third simulation may 
be explained by the difference in the energy in the system after the equilibration 
phase prior to MD production runs that would cause CLR to behave differently 
when constraints were lifted for production runs. Additionally, this could be 
attributed to localized pockets of low solvent density in the water box altering the 
small molecule’s behavior. The third simulation has CLR starting in a different 
position and orientation than the other simulations, indicating sufficient energy 
was present in the system during the equilibration phases to overcome the 
restraints imposed (10.0 kcal/mol.Å2) during these phases. Because of this, the 
distance from K453 when production runs began and restraints were lifted likely 
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contributed to the differential movement due to the inability of the hydroxyl of 
CLR to hydrogen bond to K453 in order to stabilize CLR on CRAC4 residues. 
Additionally, movement of CLR in Y450F simulations 1 and 2 (Figure 15) mimics 
the behavior of CLR in trCTD simulations 1 and 2 (Figure 11), although CLR 
remained in association with residues 450 to 453 longer in trCTD simulations, 
with CLR moving toward Y450 over time. This is distinct from K453A simulations 





Figure 14. Y450F Simulations Cholesterol and CRAC4 Interatomic Contacts 
Contacts less than 5 Å between CLR H9 atom and residues in CRAC4 shown as 
total number of contacts per frame (1ps) of each simulation. Green circles 





Figure 15. Positions of Cholesterol on CRAC4 Motif in Y450F Simulations 
CLR (stick models) coordinates in 200 ns simulations shown every 50 ns. Time 
steps shown are 0 ns (red), 50 ns (pink), 100 ns (white), 150 ns (purple), and 200 
ns (blue). Protein is shown as ribbon structure with CRAC4 residues as ball and 
stick models. A) Simulation 1 shows CLR starting on CRAC4 and migrating 
towards Y450F before migrating back to K453 in the last 50 ns of simulation time. 
B) Simulation 2 shows CLR molecule starting on CRAC4 (red) and moving away 
from K453, but staying near Y450F before moving towards residues 444 to 449 
in the end. C) Simulation 3 shows CLR moving towards residues 444 to 449 early 





Finally, the CTD simulations (Figure 16, Figure 17) showed CLR behavior 
distinct from the trCTD, K453A, and Y450F simulations. Figure 16 shows 
interactions between CLR and the two spatially distinct parts of CRAC4. For this 
set of simulations, four production runs were completed due to CLR quickly 
moving into the water box in the second simulation, which is indicated in Figure 
16 by the lack of interactions between CLR and CRAC4 residues. This was 
thought to be a rare molecular event, so an additional simulation was performed. 
For all 4 simulations, interactions between CLR and residues 450 to 453 are 
lesser in these simulations compared to trCTD (Figure 10) and Y450F (Figure 
14). Compared to K453A simulations (Figure 12), CTD simulations show almost 
no interaction with residues 444 to 449 except for a brief interaction in the third 
simulation with fewer than 5 interactions per frame and occurring for roughly 5 
ns. In Figure 17 A and B, CLR moves to other parts of the protein distant from 
CRAC4 and remains there throughout simulation time. Panels C and D show 
CLR staying closer to CRAC4 with the third simulation; this being the most 
similar to trCTD and Y450F results with CLR in the fourth simulation moving 
toward the linker part of the protein that connects the cytosolic domain to the 
transmembrane segments of BKCa (Figure 1). The fourth simulation also shows 
CLR interacting with CRAC4 residues through the first 50 ns of simulation time 
before moving to the linker region.  
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Figure 16. CTD Simulations Cholesterol and CRAC4 Interatomic Contacts 
Contacts less than 5 Å between CLR H9 atom and residues in CRAC4 shown as 
total number of contacts per frame (1ps) of each simulation. Green circles 
represent points in the simulation where K453 (BKCa residue K453) hydrogen 




Figure 17. Positions of Cholesterol on CRAC4 Motif in CTD Simulations 
CLR (stick models) coordinates in 200 ns simulations shown every 50 ns. Time 
steps shown are 0 ns (red), 50 ns (pink), 100 ns (white), 150 ns (purple), and 200 
ns (blue). Protein is shown as ribbon structure with CRAC4 residues as ball and 
stick models. A) Simulation 1 shows CLR starting on CRAC4 and moving 
towards Y450 before migrating away from CRAC4 for the remainder of the 
simulation. B) Simulation 2 also shows CLR starting on CRAC4, but it quickly 
moves away from CRAC4 to other residues in the protein. C) The third simulation 
shows CLR remaining on or near the CRAC4 residues, but moving into the water 
box around 100 ns before returning to CRAC4. D) The fourth simulation shows 
CLR remaining on CRAC4 through 50 ns and then moving away to other 





In order to better understand CLR behavior in CTD simulations, 
interactions of CLR with other CRAC motifs (Table 1) were calculated for CTD 
simulations (Figure 18). In the first simulation, CLR moves from CRAC4 after 70 
ns to CRAC7 around 100 ns exhibiting a high number of interactions, though 
sporadically, between CLR and CRAC7 residues. Inspection of the trajectory for 
this simulation shows CLR moving on and off of CRAC7 throughout the 
simulation, but a cause for this behavior could not be determined. The second 
simulation, where CLR migrated away from all CRAC4 residues very early in the 
simulation and moved into the water box, CLR returns to the protein and interacts 
with residues of CRAC6. However, CLR does not remain in contact with CRAC6 
residues, moving to non-CRAC areas of the protein. There are also a small 
number of interactions with CRAC7 residues after 10 ns in simulation 2, but they 
only reach one interatomic interaction per frame and do not indicate CLR 
interacted with multiple CRAC7 residues.  
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Figure 18. CTD Simulations of Cholesterol and CRAC4-10 Interatomic Contacts 
Contacts less than 5 Å between CLR H9 atom and residues in CRAC4 (black), 
CRAC5 (red), CRAC6 (green), CRAC7 (blue), CRAC8 (teal), CRAC9 (magenta), 
CRAC10 (orange) shown as total number of contacts per frame (1ps) of each 
simulation. Hydrogen bonds to R575 (red circles) and K613 (pink circles) shown 
for simulations where interactions with other CRAC6 or 7 motifs occurred. 
2.3.3 Importance of Hydrogen Bonding for Cholesterol Interaction 
with CRAC Motifs 
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To evaluate the importance of hydrogen bonding on CLR mobility, the 
number of hydrogen bonds between the hydroxyl of CLR and the amine side 
chain of K453 was determined for all simulations except K453A, where no 
hydrogen bonding partner is available. The calculations were performed on the 
CTD, trCTD, and Y450F constructs, which all retain K453 and are capable of 
hydrogen bonding with the hydroxyl of CLR (Figure 8). Table 2 shows the sum of 
hydrogen bonds in each simulation between the hydroxyl of CLR and the amine 
side chain of K453 in CTD, trCTD, and Y450F simulations.  
 
Table 2. Number of Hydrogen Bonds Between CLR and K453 in CTD, trCTD, 
and Y450F Simulations 

















The number of hydrogen bonds in CTD simulations is considerably less 
than the number of hydrogen bonds in trCTD simulations. This is likely due to 
K453 hydrogen bonding to E479 in the CTD construct in the modeled protein 
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(Figure 19), which prevents the side chain from being accessible to form a 
hydrogen bond with CLR. The side chain interaction with E479 is an artifact of 
the loop modeling, which involves minimization of generated models, and 
structural minimization of the protein before MD simulation. The hydrogen bond 
between K453 and E479 is not present in the crystal structure. However, after a 
several nanoseconds of simulation, K453 returns to a position where it is capable 
of hydrogen bonding with CLR, but due to unavailability in the beginning, 
simulations 1, 2, and 3 have very few hydrogen bonds. Figure 16 shows that the 
few hydrogen bonds that occur in simulation 1 occur later in the simulation 
around 60 ns, while simulation 4 shows hydrogen bonding early in the simulation 
and also retains a high number of interactions between CLR and CRAC4 longer 
than any of the CTD simulations. It is probable that the lack of hydrogen bonding 
partner availability with residue K453 and the alternative hydrogen bonding E479 
contributes to the mobility of CLR molecules in these simulations compared to 




Figure 19. Hydrogen Bond Between K453 and E479 in CTD Simulation 
Protein shown as cartoon ribbon structure. Residues shown as stick models with 




In trCTD and Y450F simulations, E479 is no longer available to hydrogen 
bond with K453 and the residue is capable of hydrogen bonding with CLR or 
water molecules instead. In the two simulations with the highest number of 
hydrogen bonds (trCTD simulation 1 and Y450F simulation 1), the times during 
thesimulation where hydrogen bonds are recorded are accompanied by greater 
numbers of interatomic interactions between CLR and residues 450 to 453 of the 
CRAC4 motif; the same pattern can be seen in CTD simulations. While CLR 
could approach and hydrogen bond with this residues from other faces of the 
protein, the steady orientation, or in some cases return to starting orientation, of 
CLR in simulations implies CLR is drawn to these motifs. However, the 
underlying cause of this has yet to be determined. Combined with the data 




with residues 450 to 453 only briefly in all three simulations, these data indicate 
that K453 is vital to the stabilization and interaction of CLR with CRAC4 and 
mutation of this residue destabilizes the interaction between CLR and other 
CRAC4 residues in BKCa channels.  
While K453 proved to be important in CLR stabilization on CRAC4, the 
other CRAC motifs (CRAC6 and 7) did not exhibit the same hydrogen bonding 
patterns as CRAC4 (Figure 18). In CTD simulation 1 where CLR migrates to 
CRAC7, only a small number of hydrogen bonds registered with K613, the 
analogous residue to K453 in CRAC7. In CTD simulation 2 where CLR migrates 
to CRAC6, a larger number of hydrogen bonds are recorded during the 
simulation with R575 and are more comparable to trCTD hydrogen bonds with 
K453. Around 130 ns there is an increase in the number of hydrogen bonds 
recorded followed by a high number of interatomic contacts, which is consistent 
with patterns seen in CRAC4. However, the largest group of hydrogen bonds 
between CLR and R575 after 180 ns do not correspond to an increase in CLR 
interatomic contacts with CRAC6 residues, as is seen in trCTD and Y450F 
simulations. This suggests CLR is approaching from one side of the protein to 
hydrogen bond with R575, but not approaching the other residues in the CRAC6 
motif. The positions of CLR on CRAC6 will be discussed in more detail in section 
2.3.5 and shown in Figure 22 These results indicate the residue analogous to 
K453 in CRAC6 (R575) plays a similar role to stabilize CLR on CRAC residues, 
but the analogous residue in CRAC7 (K613) did not show the same hydrogen 
bonding-interatomic interaction pattern as CRAC4 during simulation time. 
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2.3.4 RMSD of Cholesterol in Simulation Constructs 
To further examine differences in CLR movement, the RMSD of CLR in 
each simulation was calculated from the starting structure of each construct for 
all 200 ns of simulation time (Figure 20). Both CTD and trCTD simulations show 
RMSDs lower than 10 Å longer than either Y450F or K453A simulations, with the 
exception of simulation 2 in both trCTD and CTD constructs. Y450F simulations 
show distinctly stable RMSDs over long periods of simulations time, which is also 
reflected in the snapshots in Figure 15. The high RMSD seen in CTD simulation 
3 was a result of CLR colliding with the walls of the periodic box. The spikes in 
RMSD seen in trCTD simulation 2 and K453A simulation 2 are both caused by 
CLR briefly leaving the protein surface, but returning after a few nanoseconds of 
simulation. The K453A RMSD of around 20  for the duration of the simulations in 
all three simulations is consistent with the snapshots of K453A simulations in 
Figure 13 showing CLR staying near residues 444 to 449.  
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Figure 20. RMSD of Cholesterol in Y450F, K453A, trCTD, and CTD Constructs 
CTD and trCTD simulations show RMSDs lower than 10 Å for longer periods of 
simulation time than Y450F or K453A simulations. 
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2.3.5 Solvent Accessible Surface Area 
It was observed experimentally that truncation of CRAC motifs in BKCa 
decreases cholesterol sensitivity137 and CLR migrated from CRAC4 to CRAC6 or 
CRAC7 in CTD simulations. These two motifs (CRAC6 and CRAC7) are the 
CRAC motifs closest in proximity to CRAC4 that are not completely buried in the 
protein, like CRAC5. Hydrophobic solvent accessible surface area (SASA) was 
investigated as a possible explanation for the interaction of CLR with these 
specific sites. The CTD protein has 33.09% hydrophobic SASA, which is greater 
than the % hydrophobic SASA of any one CRAC motif in BKCa, with the 
exception of CRAC9 at 48.47%. However, because this protein has tetrameric 
quaternary structure and is in close proximity to the membrane by attachment 
through a linker to the transmembrane segments of BKCa, it is likely these 
numbers do not accurately represent the SASA of the assembled protein. 
Hydrophobic contacts between protein interfaces have previously been shown to 
play an instrumental role in assembly of the CTD tertiary structure,204 as well as 
other globular proteins205 and proteins that associate with cell membranes,206 so 
the overall hydrophobic SASA is likely to decrease in any quaternary assembly 
as these areas would no longer be solvent exposed. Also, due to several loops 
missing from the crystal structure, the modeled sections of the protein may not 
accurately represent the actual tertiary structure of the protein. However, these 
sections did not contain any of the CRAC motifs, so the accuracy of modeled 
loops was not heavily scrutinized. Additionally, only one CRAC motif, CRAC4, is 
in close proximity to the interface between two subunits in the tetrameric 
assembly (Figure 21), which was determined by examining the quaternary 
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structure of the crystal structure, and would likely have a decreased SASA in a 
tetramer. However, the simulation protein file could not be assembled as a 
tetramer without atom clashing issues. Attempts to remedy these clashes would 
alter secondary structure at the subunit interfaces, so comparable calculations 
using quaternary structures were not possible using simulation files. 
 
 
Figure 21. CRAC4 Quaternary Structure Interface 
CRac4 residues are shown as green ball and stick models. Residues from the 
neighboring α subunit are shown as grey ball and stick models. The rest of the 




CRAC6 has a relatively low % hydrophobic SASA at 10.30%, which is due 
to the fact that most of the residues belong to a beta sheet that is buried inside 
the protein (Figure 22). Examination of the CTD simulation 2 trajectory shows 
CLR interacting with residues in parts of CRAC6 and remaining stable on CRAC6 
residues before moving to another part of the protein (Figure 22). Additionally, as 
discussed in section 2.3.3, the time during simulation (after 180 ns) that 
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corresponds to the highest number of hydrogen bonds between CLR and K613 
does not indicate a high number of interatomic contacts between CLR and 
CRAC6 residues (Figure 18). Combined with CLR positioning in Figure 22, CLR 
is not in contact with most CRAC6 residues during most hydrogen bonding 
events, but remains close enough to transiently form hydrogen bonds with K613. 
However, the low level of recorded contacts with CRAC6 residues is to be 




Figure 22.Top Down View of CRAC4, CRAC6, and CRAC7 Residues and 
Cholesterol Positions from CTD Simulation 2 
All CRAC residues are represented as tubes while CLR is ball and stick 
representation. CRAC4 is shown in blue, CRAC6 is shown in yellow, and CRAC7 
is shown in magenta. Time steps shown for CLR are 0 ns (red), 50 ns (pink), 100 
ns (white), 150 ns (purple), and 200 ns (blue). Residues 287 to 387 shown in 




2.3.6 The Role of Y450 in Cholesterol Recognition 
Experimentally, the Y450F mutation on CRAC4 blunted CLR sensitivity in 
BKCa channels137 and comparison of simulations of trCTD (Figure 10) and Y450F 
(Figure 14) revealed a difference in simulation time spent in contact with K453. In 
Y450F simulations, CLR moved towards F450 and surrounding residues and 
away from K453, although it did return to hydrogen bond with K453 in Y450F 
simulation 1. trCTD simulations showed CLR remaining in contact with K453 
through hydrogen bonding longer than in Y450F simulations before eventually 
moving to other parts of the protein. Despite these findings, a quantitative 
explanation from simulation data for the difference in CLR movement could not 
be determined. 
2.3.7 Correlation of Molecular Dynamics Simulations and 
Experimental Results 
Experimentally, the K453A mutant proved to be insensitive to cholesterol, 
which is explained in MD simulations by the lack of a hydrogen bonding partner. 
Without a hydrogen bonding partner present on the motif, CLR fails to remain 
stable on CRAC4 and quickly migrates to other areas of the protein in K453A 
simulations. With the role of K453 well established as a hydrogen bonding 
partner that serves to stabilize CLR during MD simulations of trCTD, simulation 
and experimental data are in agreement. The Y450F mutant was experimentally 
insensitive to CLR and Y450F simulations do show differential CLR movement 
compared to trCTD. This is in agreement with experimental data, but the 
simulations did not provide a possible underlying mechanism for the difference in 
the Y450F mutant. 
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Finally, the experimental observation that the truncated protein is more 
sensitive (about 150% compared to WT) to CLR than the WT BKCa α subunit 
could be explained by the absence of E479 as a hydrogen bonding partner for 
K453 in the truncated protein. With K453 more readily available to hydrogen 
bond with CLR in the truncated protein, it is possible CLR remains more stable 
on this protein than in the WT, as was observed in the MD simulations. While this 
remains a possibility, other factors could influence the difference in sensitivity 
between the two, including increased flexibility of the smaller protein that could 
bring it in closer proximity to the membrane to interact with CLR and potential 
decreases in CLR residence time on CRAC4 in the larger protein due to 
competition for interactions with other CRAC motifs which lack functional 
influence due to distance from the voltage sensing domain as also observed in 
the simulation. Truncation of the protein after CRAC4 removes the inter-subunit 
CTD interface shown in Figure 21 exposing residues 444 to 449, which CLR 
migrates to readily in many of the simulations as described in section 2.3.2. This 
behavior would not be possible in a fully assembled channel since these residues 
would be buried at the interface of the α subunits. Further studies, including 
simulations with explicit membranes containing CLR and a tetrameric assembly 
of CTD protein, are needed to determine if the difference can be attributed to 
K453 flexibility or other factors. 
2.4 Conclusions 
Simulations of the CLR sensitive BKCa α subunit cytosolic domain as WT, 
truncated WT, truncated K453A mutant, and truncated Y450F mutant constructs 
provided insight into intermolecular interactions between CLR and the protein. 
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While the importance of K453 was caused by hydrogen bonding with CLR that 
stabilizes CLR on CRAC residues, a role for Y450 and an explanation of 
differential CLR behavior in Y450F simulations compared to trCTD remains to be 
determined. Further simulations of a tetrameric assembly of CTD over longer 
simulation time may provide more insight into CLR interaction with CRAC 





Multi-Generational Pharmacophore Modeling for Ligands to the Cholane 
Steroid-Recognition Site in the β1 Modulatory Subunit of the BKCa Channel 
 
3.1 Introduction 
Functional BKCa channels result from homomeric assembly of four α (slo, 
slo1) subunits. In most tissues, however, the native channel complex includes 
modulatory β subunits that modify ion channel phenotype.207 Due to the 
ubiquitous expression of the BKCa channel-forming α subunit, these channels 
play a significant role in many physiological functions including neuronal 
excitability, neurotransmission, hormonal secretion and regulation of smooth 
muscle tone.2,3 BKCa α subunits consist of seven transmembrane segments12 in 
addition to a long C-terminal tail that recognizes several physiologic ligands, 
including intracellular Ca2+.208 In contrast, BKCa β types (β1-4) are small proteins, 
each made of intracellular N- and C-termini, and two transmembrane helices 
connected by a large extracellular loop.6  
Differential expression of β subunit types across tissues allows tissue-
specific BKCa current phenotypes that contribute to cell physiology in a tissue-
specific manner. In particular, when co-expressed with the α subunit, the smooth 
muscle-abundant β1 subunit increases the channel’s apparent Ca2+ sensitivity 
and slows down channel gating kinetics.7 In smooth muscle, an increase in the 
channel’s apparent Ca2+ sensitivity allows BKCa channels to activate upon 
increase in intracellular Ca2+ levels near the BKCa channel, which are raised 
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during membrane depolarization and smooth muscle contraction.  Thus, BKCa 
channel activation results in outward K+ currents that tend to hyperpolarize the 
membrane and oppose depolarization-induced Ca2+ entry. Eventually, smooth 
muscle contraction is restrained and relaxation is facilitated.209,7 Moreover, the 
critical role of BKCa β1 subunit in smooth muscle physiology has been well 
documented: for instance, BKCa β1 knock-out mice are characterized by 
increased arterial tone.41 Decreased β1 gene expression leads to systemic 
hypertension in rats210 and increased phasic contractions in mouse urinary 
bladder.211 Considering the key role of BKCa β1 in determining smooth muscle 
tone, this subunit represents an attractive target for therapeutic developments 
against a wide clinical spectrum of prevalent human conditions associated with 
enhanced smooth muscle contraction, including bronchial asthma, systemic 
hypertension, cerebral vasospasm, erectile dysfunction, premature labor, and 
some bladder disorders.131,150,212 
There are several compounds known to modify BKCa channel function, yet 
only a few are confirmed to act via the recently identified β1 subunit cholane 
steroid-recognition site130,141 (Figure 23). Cholane steroids such as the bile acid, 
lithocholic acid (LCA), increase BKCa channel activity through interaction with β1 
subunits.130 This action is β1 subunit-specific and not observed with β2-4 subunit-
containing BKCa complexes or with homomeric α channels.133 Combined results 
from point mutagenesis, electrophysiology and computational modeling indicate 
that the cholane steroid-recognition site is located in the β1 subunit second 
transmembrane domain, with T169 playing a critical role in bile acid recognition. 
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Previous structure-activity relationship (SAR) studies indicated that the overall 
shape of the bile acid, as well as the number of hydroxyls, and placement of 
hydroxyls and carboxylic acids, were important in bile acid interaction with β1.130 
Among non-steroidal compounds, only one triterpenoid, 3-hydroxyolean-12-en-
30-oic acid (3-HENA)141 has been reported to specifically target β1-containing 
BKCa complexes. Moreover, although there are several ligands with β1-dependent 
effects on BKCa channel opening, only LCA and 3-HENA have been reported to 
interact with a defined recognition site141 making the other ligands less useful in 
determination of a pharmacophore. 
 
 
Figure 23. BKCa β1 Selective Activators 
Lithocholic acid (LCA), 3-hydroxyolean-12-en-30-oic acid (3-HENA), and 
dehydrosoyasaponin I (DHS-I). Points on lithocholic acid were selected for 
distance constraints used in initial pharmacophore searching. 
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High-resolution structures of the BKCa α gating-ring are available,53 
however structures of neither the complete α subunit nor any β subunit are 
available. Given this deficit in receptor structural data, the present study focuses 
on ligand-based pharmacophore model development using BKCa-ligand 
structures found by our groups to selectively target the cholane steroid-
recognition site in BKCa β1. As new data and techniques have become available, 
multiple iterations of pharmacophore modeling have led to a better understanding 
of how pharmacophore features effect model performance, yet lack of structural 
diversity amongst known ligands has posed a significant challenge. The best 
performing model was used to search the PubChem compound database,213 
which led to the discovery of several novel compounds that fit structural criteria 
posed by the β1 steroid-sensing site while offering structural diversity over known 
ligands.  The current study sets the stage for future in vitro and/or in vivo testing 
of these newly identified compounds and to further assess accuracy of the 
model, make further refinements, and confirm which of the candidate compounds 
contribute to the chemical diversity of β1-selective agents.
3.2 Methods 
3.2.1 Pharmacophore Model Development 
Initial modeling was performed using the Molecular Operating 
Environment (MOE)191 2006.08 software package. Stochastic conformational 
searching was performed on LCA (Figure 24 #14) using the MMFF94x forcefield, 
chosen for its ubiquitous use with small organic molecules, with gas phase 
solvation and a dielectric of zero. MMFF94x is an unpublished version of the 
MMFF94 forcefield214 where conjugated nitrogen atoms are treated as planar 
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versus tetrahedral. The carboxylic acid of LCA was deprotonated to represent the 
expected prevalent ionization state of the molecule at physiological pH. Since 
LCA was reported to be the best activator among the 13 bile acids tested in a 
previous SAR study,130 the lowest energy conformation of LCA was used to 
establish distance constraints for crude pharmacophore searching in the National 
Cancer Institute (NCI) database (http://cactus.nci.nih.gov/ncidb2.2/) using the 3D 




Figure 24. Compounds Used in Pharmacophore Model Development and Testing 
Active compounds are indicated with a + before the compound number. Inactive 

















Compound # n1 R1 n2 
 +25 3 COOCH3 4 
-26 4 COOCH3 5 
+27 4 COOH 5 
+28 3 COOH 4 
-29 2 COOH 3 
-30 4 COOCH3 7 
-31 4 COOCH3 9 
-32 4 COOH 7 
-33 4 COOH 9 
+34 3 COOCH3 5 
+35 3 COOH 5 
+36 2 COOCH3 4 
-37 2 COOH 4 




R1 R2 R3 R4 R5 
-1 B  - - CH2COOH - 
+2 A    CH2COOH - 
-3 A   - CH2NH2 - 
-4 A   - CH2CH2OH - 
-5 A   - 
 
- 
-6 A   - CH2CH2I - 
-7 A   - CH2CH2SO4H - 








+10 A   - CH2CN - 
-11 A   - 
 
- 
+12A   - CH2CH2CN - 
-13 A   - 
 
- 
+14 A   - CH2COOH - 
+15 A   - CH2COOH OH 
+16 A   - COOH - 
-17 A   - CH2COOH - 
-18 A   - CH2COOH - 
-19 B  - - CH2COOH - 
+20 A   - CH2COOH - 
-21 A   - CH2COOCH3 - 
+22 A   - NO2 - 
+23 A   - CH2NO2 - 
+24 A   - CH2COOH OH 
O
Bile Acids and Derivatives 
Carbon Chains 
Miscellaneous Compounds  
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Compounds were considered “active” if they produce an increase in 
channel activity within 20% of the activity increase observed with LCA. 
Compounds were screened at either 45 µM (the EC50 of LCA) or 150 µM (the 
Emax of LCA).134 
A 2nd generation model (Figure 25) was made using the Pharmacophore 
Elucidator feature in MOE 2009.10 to allow for searching of databases other than 
the NCI database. LCA and deoxycholic acid (#24), previously established 
activators of β1-containing BKCa channels,134 were used as positive examples on 
which to train the model. Three additional bile acids that do not increase channel 





Figure 25. All Generations of Pharmacophore Models With Lithocholic Acid 
LCA is mapped to all generations of pharmacophore models for comparison. 
Magenta features represents a hydrogen bond donor, green features represent 
hydrophobic centers, teal features represent hydrogen bond acceptors, and the 
red feature represents a carboxylic acid bioisostere. In the 5th generation model 
the teal feature is a combination of a hydrogen bond acceptor and an anion. In 
the 6th generation model the teal feature is a hydrogen bond acceptor projection 
from overlapped hydrogen bond donors in the model training set. Numerically 
labeled features are described in Table 5 and Table 6. First generation crude 
model of pharmacophore using atomic distances between points on LCA 
(shown). Second generation model developed for conformational database 
searching. Third generation model using 5 pharmacophore features. Fourth 
generation model generated with more structurally diverse compounds. Fifth 
generation model with radius reduced pharmacophore features (see Table 5 for 
radii). Sixth generation model using ligand projections for a hydrogen bond 
acceptor (1) and three hydrophobic features (2-4).  
! 1st Generation 2nd Generation 


























After the discovery of 3-HENA (#39) as a non-steroidal β1 activator, a 3rd 
generation model was developed due to the structural diversity offered by 3-
HENA.141 The 3rd generation model (Figure 25) was generated using LCA and 3-
HENA as active compounds, while using two new compounds as inactive 
compounds to train the model (#8, 46) in addition to #17, which was used as an 
inactive compound in the previous generation. These compounds were selected 
to provide more structural diversity over inactive compounds used to train the 2nd 
generation model. 
The 4th generation model (Figure 25) was obtained using LCA (Figure 24 
#14), 3-HENA (#39), and a synthetic bile acid containing a cyano functional 
group in place of the lateral chain carboxylic acid (#10) as active compounds. 
Three inactive compounds were selected for structural diversity, which are shown 
in Figure 24 as compounds #1, 42, 45.  
Refinements were made to the 4th generation model to yield a 5th 
generation model (Figure 25), as follows. 1) The radii of the pharmacophore 
features were reduced to be more exclusive, 2) the hydrogen bond acceptor 
feature was changed to include anionic compounds, 3) feature 2 was moved to 
align better with the steroid nucleus, and 4) features 1, 3, and 4 were made 
“essential” features.  Thus, any screened compound would contain at least these 
three features.  
Finally, a 6th generation model was developed using newer techniques 
available in MOE 2013.08 software that include ligand projection features for 
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hydrogen bond donors and acceptors. The same training set of compounds used 
to develop models 4 and 5 was used to develop model 6 (Figure 25).  
3.2.2 Model Evaluation 
Test set compounds and their activities were obtained from various 
publications130,134,215,216 and unpublished data from our experimental 
collaborators, Dr. Alex Dopico and Dr. Anna Bukiya, at the University of 
Tennessee Health Science Center. A conformational database was generated for 
test set compounds using LowModeMD conformational searching217 and the 
MMFF94x forcefield in MOE 2013.08. Conformations were discarded if their 
internal energy exceeded the lowest energy conformation by 50 kcal/mol to 
provide more conformational diversity over the default 7 kcal/mol cutoff. Any 
compounds used to train any generation of model, compounds #1, 8, 10, 14, 17, 
18, 19, 24, 39, 42, 45, and 46 were removed from the standard test set so all 
models would be evaluated with the same database. Thirty-seven compounds 
remained to calculate pharmacophore validation metrics. Sensitivity, specificity, 
percent yield of actives, enrichment, and accuracy were calculated for each 
model, as discussed in detail by Triballeau et al.218 Sensitivity (Equation 1 below) 
represents the ability of the model to correctly pick out actives, while specificity 
(Equation 2) indicates the model’s ability to correctly reject inactive compounds. 
The yield of actives (Equation 3) indicates the proportion of active molecules 
selected by the model. Enrichment (Equation 4) is a measure of how well the 
model enriches the hit list with actives compared to the proportion of actives in 
the whole test set. Accuracy (Equation 5) is a measure of how well the model can 
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correctly discriminate between experimentally active and inactive compounds. A 







































In Equations 1-5, TP is the number of true positives, FN is the number of 
false negatives, TN is the number of true negatives, FP is the number of false 
positives, n is the number of compounds selected by the model, N is the total 
number of entries in the database, and A is the total number of active 
compounds in the database. In this use, a positive compound is one identified to 
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be active by the model, while a negative compound is identified to be inactive by 
the model. The term true indicates the result from the model agrees with the 
experimental result, while false indicates a result from the model that disagrees 
with the experimental result. For example, a true positive is a compound 
predicted by the model to be active that is experimentally active and a false 
positive is a compound predicted by the model to be active that is experimentally 
inactive. For Equations 1, 2, 3, and 5,a  value closer to one is a good result. For 
Equation 4, a value greater than one is a good result. 
3.2.3 Database Searching 
Database searching was performed in a 3D compound database, which 
contains up to 10 conformations per molecule, downloaded from the PubChem 
FTP site 
(ftp://ftp.ncbi.nlm.nih.gov/pubchem/Compound_3D/10_conf_per_cmpd/). The 
compound databases were imported into MOE 2012.10 and the 3rd generation 
model was used to query the database. An additional search was performed 
using the 6th generation model to search the 3rd generation results from 
searching the PubChem database. The number of compounds returned from the 
database search was reduced by excluding anything with a LogP below 1.7 and 
above 5.9. These values represent the LogP (the octanol/water partition 
coefficient) values of compounds #25 and #39, respectively, and were used 
because they are the highest and lowest LogP values of the most potent known 
activators. The molecular weights of compounds #25 and #39 were used to 
further reduce the number of compounds with a range of 198.2620 to 455.7030. 
Finally, since the steroid recognition site is located in the transmembrane portion 
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of the helix, compounds that would be too polar for membrane insertion were 
removed. This was accomplished by calculating the number of non-carbon heavy 
atoms in each molecule. Any compound with more than four non-carbon heavy 
atoms was removed from the hit list, since all but one known active (#20) contain 
no more than four non-carbon heavy atoms. 
Clustering was performed on the remaining compounds by first calculating 
MACCS structural keys (a binary description of structure)219 and similarity was 
determined using a 65% Tanimoto coefficient (a measure of similarity between 
two sets of compounds) similarity220 threshold. The clustering overlap threshold 
was set at 65% or greater; meaning two compounds would require 65% or 
greater Tanimoto coefficient similarity of their structural neighbor lists to be 
placed in the same cluster. The formal charge on compounds in each cluster was 
used to further reduce the number of compounds by eliminating compounds with 
no formal charge, leaving only compounds with -1 or -2 charges to mimic the 
charge on the most active compounds (LCA and 3-HENA). 
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3.3 Results and Discussion 
3.3.1 Model Selection 
For the 1st generation model, three points were established on the LCA 
molecule (Figure 23) that were based in part on a previous study;134 two points 
underscored the importance of the lateral chain carboxylic acid and the A ring 
hydroxyl (point 1 to point 3). A carbon in the steroid nucleus was selected as the 
third point to represent the concavity of LCA due to a cis A-B ring junction and is 
shown in Figure 25. The distances between the points and the ranges used to 
search the NCI database are shown in Table 3. Ranges were used to allow some 
flexibility outside of the values determined from a single conformation of LCA as 
opposed to using exact values, which would be overly restrictive. Since LCA has 
a LogP of 6.05, a LogP range of 4 to 8 was also used as additional search 
criteria to narrow the results. Due to the limitations of the browser-based search 
features of the NCI database, this method was abandoned in favor of more 
robust three-dimensional model development using MOE. While the 1st 
generation model provided a starting point, it was inherently limited to 3D 
distance descriptions of the pharmacophore and did not explicitly involve inactive 
compounds for model development. Results of virtual screening will be discussed 














1→2 4.93Å 4.60Å→5.80Å  
1→3 10.48Å 9.00Å→11.00Å 




The 2nd generation pharmacophore used LCA and deoxycholic acid as 
active compounds to develop the model and provided a more robust description 
of the steroid recognition site in β1 by using four features to describe the 
pharmacophore in three dimensions. The set of potential models was analyzed 
for hydrophobic features that were spaced to convey the “bean” shaped 
concavity of LCA. Candidate models were also screened using the criteria that 
the model should contain a hydrogen bond donor feature aligned with the 
hydroxyl of LCA and a hydrogen bond acceptor feature aligned with the 
carboxylate of LCA as these two functional groups very likely play a role in the 
interaction with β1. The top candidate model was evaluated for accuracy using a 
test set of compounds with experimentally known activity on β1-containing BKCa 
channels excluding the compounds used to train all models so that all models 
were evaluated using the same set of compounds. 
For the 3rd generation model, the top candidate model was selected from 
the potential models using the same selection criteria as the 2nd generation 
model.  An additional feature, however, was allowed in the 3rd generation model: 
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a carboxylate ion bioisostere feature that allows other functional groups in place 
of the carboxylate.  
The top candidate pharmacophore model in the 4th generation was 
selected using the previously mentioned criteria for the 2nd generation model, but 
the placement of hydrophobic features was more heavily scrutinized than 
previously. This was accomplished by ensuring any candidate models had 
hydrophobic features in the steroid nucleus of the active molecules and not on 
methyl groups. 
For the 6th generation model, the two top models ranked by the model 
development algorithm were selected for evaluation with the test set. The models 
differed only in the first feature, where the top model had a hydrogen bond donor 
projection and the second ranked model had a hydrogen bond acceptor 
projection. These projections place pharmacophore features on the projected 
interaction sites for hydrogen bond donor and acceptor atoms in a molecule and 
could find a partner hydrogen bond acceptor or donator interaction partner 
common to all activators of the cholane steroid-recognition site. The second 
model was selected as the 6th generation model after evaluation of performance 
against the test set compounds. 
Distances between pharmacophore features in models 2-6 are provided in 
Table 4 and the radius of each feature is given in Table 5. Because models are 
generated using conformational databases of actives and inactive compounds, 
distances between similar features are not necessarily the same. The radii of 
pharmacophore features were generally left at default values except in the 5th 
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generation model where feature radii were intentionally decreased to increase 
specificity.  
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1→2 4.08 4.60 5.33 5.10 5.12 
1→3 9.58 9.63 11.95 11.95 7.68 
1→4 8.99 9.00 8.57 8.57 13.00 
1→5 - 10.18 - - - 
2→3 7.61 7.39 9.43 9.27 2.58 
2→4 5.15 4.56 4.42 4.35 8.64 
2→5 - 7.76 - - - 
3→4 5.68 5.97 5.42 5.42 7.16 
3→5 - 0.63 - - - 

















1 1.4 1.4 1.6 1.0 1.0 
2 1.4 1.4 1.4 1.3 1.4 
3 1.4 1.4 1.6 1.3 1.4 
4 1.4 1.4 1.4 1.3 1.4 




3.3.2 Model Performance 
The metrics used to evaluate the models are shown in Table 6. These 
values are reported both because they represent the most commonly reported 
















Positives 9 5 10 9 13 
False 
Positives 15 3 15 14 15 
True 
Negatives 7 19 7 8 7 
False 
Negatives 6 10 5 6 2 
Sensitivity 0.60 0.33 0.67 0.60 0.87 
Specificity 0.32 0.86 0.32 0.36 0.32 
Yield of 
Actives 0.36 0.63 0.40 0.39 0.46 
Enrichment 0.89 1.54 0.99 0.97 1.15 




The 2nd generation model scored comparably to the 4th and 5th generation 
models (Table 6) with the standard test set in some calculated metrics, but was 
lower in a few metrics. Compared to the 4th generation model, this model was 
0.07 lower in sensitivity, 0.04 lower in yield of actives, 0.10 lower in enrichment, 
and 0.03 lower in accuracy. This indicates the inclusion of more recently tested 
compounds with greater activity in the 4th generation training set led to 
improvements in model performance. 
The 3rd generation model featured a fifth pharmacophore feature, which 
more than doubled the specificity, increased the yield of actives by 0.27, the 
enrichment by 0.65, and the accuracy by 0.22, but had a sensitivity almost half 
that of the 2nd generation model with the standard test set. Additionally, the 
enrichment of the hit list with active compounds was greater by 0.53 in the 3rd 
generation model and was the greatest enrichment of any of the models 
generated. The fifth feature was a carboxylate bioisostere intended to improve 
structural diversity in any selected compound. The low number of true positives 
and false positives indicate the fifth feature of this model is overly restrictive 
compared to four feature models. While this fifth feature did improve the model in 
several metrics, due to the large decrease in sensitivity, the placement and type 
of feature was further investigated in efforts to produce a model that better 
identifies the active compounds as true positives. 
For the 4th generation model, the three most active compounds were used 
to train the model (#10, 14, 39). The drop in specificity, or true negative rate, of 
0.54 compared to the 3rd generation model indicates that the 4th generation 
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model cannot correctly eliminate inactive compounds as well as the 3rd 
generation. This model outperformed the 3rd generation model only in sensitivity 
by 0.34, so further refinements were sought to improve upon the 4th generation 
model, without sacrificing sensitivity as was seen in the 3rd generation model. 
In an effort to improve specificity of the 4th generation model, the radii of 
features were reduced and location of the features were moved to centralize the 
features in the steroid nucleus to yield the 5th generation model. While the 
specificity did improve to be better than the 2nd generation model by 0.04, the 
sensitivity, or true positive rate, declined by 0.07 compared to the 4th generation 
model to become equivalent to the 2nd generation model. Other metrics remained 
similar between 4th and 5th generation models. 
The 6th generation model, which used the newer model development 
protocol in MOE 2013.08, provided a significant improvement in sensitivity of 
0.20 over the previous best 4th generation model and 0.54 better than the 3rd 
generation model. The specificity of the model was on par with the 4th generation 
model, but 0.04 lower than the 5th generation model and 0.54 lower than the 3rd 
generation model. Accuracy improved to 0.54, which is 0.08 better than the 4th 
and 5th generation, but 0.09 lower than the 3rd generation model. Enrichment also 
improved over 4th and 5th generation by 0.16 and 0.18, respectively, but was 0.39 
behind the 3rd generation model. 
The major difference in sensitivity and specificity for the 3rd and 6th 
generation models demonstrates the biggest issue with pharmacophore model 
development for β1 so far. With current models, any increase in sensitivity causes 
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a decrease in specificity. With the 6th generation being overly generous in 
selecting compounds as active and the 3rd generation model being much more 
discriminating with the test set compounds, a search with both models would 
eliminate a large number of inactive compounds using the 3rd generation model 
and then filter additional inactive compounds out using the 6th generation model 
(discussed in section 3.3.3 and Table 7 below). Since the PubChem database 
contains over 33 million compounds, the more selective nature of the 3rd 
generation model helps to reduce the number of compounds returned from the 
search of a database that large. Subsequent screening with the 6th generation 
model serves to filter additional inactive compounds while retaining the majority 
of active compounds due to the very high sensitivity of the model.  
3.3.3 Virtual Database Screening Results 
The 1st generation pharmacophore search of the NCI database yielded 6 
compounds, but due to limitations on availability from NCI none of the 
compounds were available for screening. Also, the limitations of the web 
browser-based query in the NCI database with distances assigned to atom types 
led us to pursue a 3D pharmacophore model with feature annotations. However, 
the distance constraints established for the NCI search were later used to guide 
development of potential 2nd generation models. Development of 3D models also 
allows for searching of databases other than NCI.  
A summary of the 3rd generation search and filtering results along with the 
results from the 3rd and 6th generation combined search are provided in Table 7. 
Since the 3rd generation model had the highest specificity and enrichment, and 
the PubChem database contains more than 33 million compounds, this model 
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was selected to reduce the size of the potential hit list from pharmacophore 
searching. Additionally, since compounds must be assayed using the patch 
clamp technique, which is time-consuming and not a high-throughput screening 
method, fewer compounds are preferred to reduce the labor and cost associated 
with this experimental technique. Initially, there were 317,771 compounds 
returned by the model. Because the laborious nature of visually inspecting over 
300,000 compounds, filters were applied to the hit list to further reduce the 
number of compounds returned by the pharmacophore search. The upper and 
lower limits of the best known activators were used to filter by molecular weight, 
LogP, and the number of non-carbon heavy atoms. This removed any 
compounds that were unlikely to be activators based on our current 
understanding of the pharmacophore by removing compounds that would be too 
large for the recognition site or too polar for membrane partitioning. Since the 
inactive compounds have a larger LogP range of 0.47 to 8.0 and a larger 
molecular weight range of 142.154 to 516.787 compared to a LogP range of 1.7 
to 5.9 and a molecular weight range of 192.262 to 455.703 for active compounds, 
using these filters should further remove inactive compounds. Additionally, 
restricting the number of non-carbon heavy atoms reduced the number 
compounds that would not insert well into the membrane to access the steroid 
recognition site. The total number of compounds was reduced to 7,582 after all 
filters were applied. 
 
92 
Table 7. Number of Compounds Returned by Pharmacophore Searching 







Compounds 317,771 243,119 30.7% 
LogP and Molecular 
Weight Filtered 52,248 41,148 27.0% 
Non-Carbon Heavy 
Atom Filtering 7,582 6,962 8.9% 




Using the combined 3rd generation and 6th generation models to search 
produced 30.7% fewer compounds than the 3rd generation model alone before 
any filters were applied. After filtering by LogP, molecular weight, and 
compounds with fewer than four non-carbon heavy atoms the difference in the 
two databases decreased to 8.9%. Since the percent difference is not that large 
after all filters were applied, the combined search approach did not provide a 
significant advantage over just using the 3rd generation model and filters for 
database searching, so screening compounds were selected from the 3rd 
generation model search results without secondary filtering by the 6th generation 
model. If a smaller database were being utilized for searching that did not require 
additional filters to produce a manageable number of results, the two model 
approach would provide the advantage of reducing the number of compounds by 
~30%, with most of the compounds being inactive due to the high sensitivity of 
the 6th generation model. 
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Structural similarity clustering of the 3rd generation model search results 
was accomplished using MACCS structural keys to fingerprint molecules and 
Tanimoto similarity. A total of 953 clusters were produced at a 65% similarity 
threshold with the largest cluster containing 5,443 of 7,582 compounds. The 
formal charge calculations provided 7,193 compounds with a charge of -1 or -2. 
These cutoffs were selected due to the -1 charge on the two most potent 
compounds, LCA and 3-HENA. However, because the synthetic LCA derivative 
cyano compounds are active, this method had the potential to remove 
compounds that could be activators of BKCa through β1. 
All clusters were visually inspected, but the largest cluster (cluster 1) 
contained bile acid derivatives and triterpenoids similar to LCA and 3-HENA, as 
well as many compounds with structural diversity over current test and training 
set compounds (Figure 24). During visual inspection, bile acids, carbon chains 
similar to compounds #25-38, compounds similar to 3-HENA, or compounds with 
more than two hydroxyl groups in the portion of the molecule that should be 
inserted into the membrane were removed as possible candidates in an effort to 
improve the structural diversity of tested compounds. Since the structure-activity 
relationships of bile acids have been extensively characterized already,130,134 
further testing of additional related examples would not prove as useful as more 
structurally diverse compounds (Figure 26). The choice of two hydroxyls was 
made to maintain low enough polarity for membrane insertion since a previous 
SAR study indicated that more than one hydroxyl facing the β1 transmembrane 
region can reduce a ligand’s biological activity, yet removing all hydroxyls from 
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the bile acid molecule abolished bile acid activation of β1 subunit-containing BKCa 
channels.130 Optimally, a compound would have no more than one hydroxyl, but 
the single hydroxyl cutoff proved too restrictive.  
Thirty-three compounds were selected by visual inspection, but since 
PubChem database contains both commercially and non-commercially available 
compounds, only 16 (Figure 26) had commercial vendors and will be purchased 
for in vitro testing. Although many compounds selected by visual inspection were 
not commercially available, the seven compounds denoted with an asterisk on 
the right side of Figure 26 are commercially available alternative compounds that 
are structurally similar to ones that were not available. These compounds were 
suggested by PubChem as structurally similar to the originally selected 
compound and were also in the compound hit list. Since many compounds are 
structurally similar in PubChem, only one compound was picked from groups of 
structurally similar compounds, but commercial availability was not determined 
until after visual inspection of the hit list. 
Ongoing In vitro testing by our experimental collaborators of compounds 
selected by the 3rd generation pharmacophore will provide final validation of the 
value of the model in selecting active compounds and will help to determine 
whether these candidate compounds are indeed β1-selective agents. Any new 
compounds with novel substructures will fuel further improvements in this 
pharmacophore model or future generations of models to produce a robust virtual 
screening method to find β1-selective agents.  
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Figure 26. Commercially Available Compounds Selected from PubChem 
Database with Compound ID (CID) Numbers 
Compounds were selected by visual inspection of structural similarity clusters. 
Compounds above the black line came from the largest cluster of 5,443 
compounds. Compounds with an asterisk (right side of figure) are commercially 
available alternatives suggested by PubChem for compounds that were not 
available. These compounds were verified to have been selected by the model 




Our pharmacophore model represents a first step in developing a robust 
tool for the discovery of novel activators of the β1 steroid recognition site. While 
iterative improvements in pharmacophore modeling and new information have 
advanced the pharmacophore model over time, further improvements are still 





Expression, Purification, and Functional Studies of the Modulatory β1 





With recent studies showing that genetic mutations221,84 or genetic 
knockout41 of the β1 subunit of the BKCa channel have a deleterious effect on the 
subunit’s physiological function, understanding the protein’s structure will lead to 
new therapeutic options for treating BKCa channel-linked diseases. Thanks to 
recent advancements in stabilization of purified membrane protein samples and 
solution nuclear magnetic resonance spectroscopy (NMR) data acquisition,222 
structural characterization of the β1 subunit has become more feasible. However, 
the protein must first be expressed, purified, and shown to possess native tertiary 
structure through functional studies. While the most relevant β1 proteins to 
structurally characterize are derived from mammalian expression systems, 
because of the low yield and high cost of mammalian protein expression 
systems, this approach is not viable. Additionally, the large quantity of protein 
required for solution NMR experiments makes protein expression in Escherichia 
coli is the most viable, cost-effective option.223 
Since E. coli utilize different and fewer post-translation modifications, 
which are used for protein structure and trafficking in mammalian systems,224 the 
E. coli expression system can sometimes create unusable protein samples with 
incorrect folding or insoluble aggregates called inclusion bodies. However, E. coli 
bacterial expression systems have been used extensively to successfully 
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produce protein samples for structural characterization by X-ray crystallography, 
NMR, or cryo-electron microscopy with mammalian expression systems 
accounting for less than 0.5% of proteins deposited in the Protein Data Bank.223 
Eukaryotic membrane protein expression in E. coli has faced significant 
challenges ascribed to disruption of cellular processes sometimes leading to cell 
death or halted cell growth and division.180 However, newer methods to control E. 
coli stress responses to eukaryotic membrane protein expression181 and the 
development of new expression vectors using various native E. coli proteins as 
fusion protein partners225 have led to improvements in yield. Over-expression of 
membrane proteins as inclusion bodies, which typically requires denaturation and 
lengthy refolding procedures, is traditionally viewed as sub-optimal because of 
low yields of functional protein.226 However, newer methods227,228 allow for more 
efficient, higher yield production of proteins from inclusion bodies. 
While traditional expression vectors, like pET-28a (Novagen), contain 
useful protein tags for purification, newer expression vectors that offer enhanced 
expression through protein fusion partners serve to improve expression and 
purification of many recombinant proteins from E. coli cells.225 For example, the 
use of maltose binding protein (MBP) enhances the solubility of many proteins 
while also serving as an affinity chromatography tag that can bind to dextrin 
sepharose beads to aid in purification from cell lysate.229 While the hexahistidine 
tag (6x-His tag) has seen ubiquitous use for immobilized metal affinity 
chromatography (IMAC) purification,229 protein samples are not typically >95% 
pure after IMAC, so these solubility tags are typically used in conjunction with 
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other common forms of purification including size-exclusion and cation exchange 
chromatography.  
The vectors utilized in this study to express protein are shown in Figure 
27. The pMCSG series of vectors were developed by the Midwest Center for 
Structural Genomics and the two used in this study, pMCSG19 and pMCSG29, 
both contain MBP fusion tags, a tobacco vein mottling virus (TVMV) protease 
cleavage site, a His tag for IMAC purification, a tobacco etch virus (TEV) 
protease cleavage site, and an ampicillin selection marker.225 The inclusion of the 
two different cleavage sites allows for selective cleavage of only the MBP fusion 
protein or both the His tag and the fusion partner. The vectors vary in that 
pMCSG19 has the MBP fusion on the N-terminal end of β1 and contains a 6x-His 
tag, while pMCSG29 has the MBP fusion on the C-terminal end of β1 and has a 
10x-His tag. Both of these vectors utilizate ligation independent cloning (LIC) 
techniques to insert the desired gene by utilizing long DNA overhangs to bind the 
gene and plasmid together, which negates the need for the long DNA ligase step 
of traditional cloning.230,231 Additionally, pE-SUMOpro (LifeSensors) utilizes a 
small ubiquitin-like modifier (SUMO) fusion tag that enhances solubility and 





Figure 27. Bacterial Protein Expression Vector Constructs 
These vectors were the first two constructs used for expression trials of the β1 
subunit of the BKCa channel. pE-SUMOpro contains a 6x-His tag (orange) for 
affinity chromatography purification, a SUMO fusion protein (blue), a SUMO 
Protease 2 cleavage site (red) to remove the fusion partner, and the inserted 
gene (green). The pET-28a construct contains a 6x-His tag (orange), a Thrombin 
protease cleavage site (red) to remove the 6x-His tag, and the inserted gene 
(green). The pMCSG19 construct contains an N-terminal maltose binding protein 
fusion partner (blue) followed by a TVMV cleavage site (purple), a 6x-His tag 
(orange), a TEV cleavage site (teal), and the β1 gene (green). pMCSG29 
contains the β1 gene (green), a TEV cleavage site (teal), a 10x-His tag (orange), 







To further optimize expression of membrane proteins, E. coli cell lines 
BL21 (DE3) and C43 (DE3)233 can be utilized. BL21 cells are standard E. coli 
expression cells, while the C43 line is a derivative of BL21 that was shown to 
overexpress membrane proteins better than BL21.233,234 While C43 cells were 
first published in 1996, it was recently discovered that C43 cells contain three 
mutations in T7 RNA polymerase that delay the onset of transcription therefore 
slowing the production of protein and potentially reduce formation of insoluble 
protein aggregates.182 These cell lines, along with the four expression plasmids, 
were used to determine the optimum expression conditions to produce β1 protein 
in E. coli. Overcoming challenges in expression of membrane proteins is followed 
by challenges in maintaining hydrophobic transmembrane segments in aqueous 
solution, with several viable options available. 
As membrane proteins have hydrophobic outward-facing residues, they 
require the non-polar cell membrane environment (Figure 28) to maintain proper 
structure and function. Similarly, purified membrane proteins must also be 
embedded in a membrane-like environment suitable for study with NMR. Since 
cells are too large to tumble quickly enough for study with NMR as they would 
have rapid T2 relaxation times,235 other methods have been developed to 
maintain a membrane environment while also allowing the protein to tumble at a 
rate compatible with solution NMR experiments. The use of detergents that form 
micelles (Figure 28) small enough to rapidly reorient provides a membrane-like 
environment while still allowing for the protein-micelle complex to rapidly reorient 
during NMR data collection. Various detergents have been employed to produce 
102 
NMR structures of membrane proteins including, but not limited to sodium 
dodecyl sulfate (SDS), n-dodecylphosphocholine (DPC), and 1,2-diheptanoyl-sn-
glycero-3-phosphocholine (DHPC)222 and will be discussed in more detail in 
section 4.3.3. Newer techniques, like lipid nanodiscs,236 offer advantages over 
micelles by preventing aggregation and producing monodispersed protein-lipid 
complexes, but these systems require expertise in nanodisc preparation. For this 








Since β1 has not been expressed and purified from E. coli before, 
functional assessment of the protein produced is a necessity. Because 
expression of non-native protein can produce incorrect folding as discussed 
previously, experiments showing the purified protein can bind known ligands or 
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exhibit wild type modifications of BKCa channel function when reconstituted with α 
subunits are needed to justify the time and expense of NMR experiments. 
Current techniques for assessing β1 involve patch-clamp techniques and channel 
current recordings involving the α-β heterooctomer,133 however, no functional 
assays exist for β1 alone. While several methods were attempted after 
successfully expressing and purifying the protein, none of the experiments 
produced results indicating the protein is in a functional, native-like fold. 
4.2 Methods 
All molecular biology experiments were based on standard protocols from 
Molecular Cloning: A Laboratory Manual by Maniatis et al.238 Examples of 
experiments performed are given below.  
4.2.1 Preparation of β1 DNA for Subcloning 
The Rattus novergicus cDNA for the β1 subunit of the BKCa channel was 
obtained from the lab of Dr. Alex Dopico at the University of Tennessee Health 
Science Center (UTHSC, Memphis, TN). The mRNA sequence information can 
be accessed through the National Center for Bioinformatics (NCBI) GenBank239 
system using accession code FJ154955.1 (http://www.ncbi.nlm.nih.gov); the 
DNA was provided in pcDNA3.1 (Invitrogen), a mammalian expression vector. 
Initial attempts at expression using the R. novergicus gene were unsuccessful. 
To improve expression, the gene was optimized for E. coli codon usage using the 
GeneArt service (Life Technologies) to replace codons rarely used in E. coli in 
the DNA sequence. For the E. coli codon optimized DNA sequence as well as 
the protein sequence of β1 see Appendix A. The optimized gene was received in 
a non-expression vector, pMA-T, containing NdeI and XhoI restriction 
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endonuclease sites before and after the gene, respectively. These restriction 
enzyme sites made it possible to excise the gene using these enzymes and 
subclone directly into pET-28a (Novagen, Figure 27) without the need for 
polymerase chain reaction (PCR) intermediates.  
Plasmid propagation was accomplished using the NovaBlue cell line, a 
specialized E. coli cell line known to produce large quantities of plasmids. The 
pMA-T plasmid DNA containing the β1 gene was used to transform NovaBlue E. 
coli competent cells (EMD Biosciences) using a standard heat-shock protocol. 
Transformation was completed by adding 3 µL of 25 ng/µL purified DNA to a 
sterile vial containing 25 µL of NovaBlue competent cells. The cells and DNA 
were allowed to incubate on ice for 30 minutes before being placed in a 42˚C 
water bath for 30 seconds. The vial was then placed back on ice for 5 minutes 
before adding 250 µL of SOC (super optimal broth with catabolite expression) 
media (Cellgro) to the vial followed by agitation on an orbital shaker at 37˚C and 
250 rpm. After one hour, the tubes were removed from the orbital shaker and 50 
µL of the bacterial solution was plated on a sterile 10 mL lysogenic broth (LB) 
agar plate containing 1 µg/mL ampicillin. The inoculated plate was placed in an 
incubator at 37˚C overnight. Each colony selected from the plate after incubation 
was used to inoculate 10 mL of LB media containing 1 µg/mL of ampicillin in a 
sterile tube. The 10 mL cultures were left overnight in an orbital shaker at 37˚C 
and 250 rpm. The following morning the cells were pelleted by centrifuging at 
8864.5xG for 10 minutes and the plasmid DNA was purified from E. coli cultures 
using a QIAprep Spin Miniprep Kit (Qiagen); manufacturer’s instructions were 
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followed. DNA concentrations were determined using standard ultraviolet 
spectroscopy protocols.238 Purified DNA was sequenced by the UTHSC 
Molecular Resource Center (UTHSC MRC, Memphis, TN) and then translated 
into the corresponding amino acid sequence using the ExPASy240 Translate tool 
(http://web.expasy.org/translate/). The translated sequence was aligned with a 
translated form of the GenBank sequence using the NCBI Protein BLAST 
algorithm241 (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
4.2.2 Excision of β1 Gene and Ligation Into pET-28a 
After sequencing results verified that the plasmid contained the correct 
sequence, the purified pMA-T DNA was digested using NdeI and XhoI to excise 
the β1 gene. The reaction was prepared with 1 µL of NdeI (20,000 U/mL, NEB), 1 
µL of XhoI (20,000 U/mL, NEB), 0.5 µL of 10 mg/mL purified bovine serum 
albumin (BSA, NEB), 2 µL of NEB 10X concentrated React 4 buffer, 5 µL of 289 
ng/µL purified pMA-T β1 DNA, and 10.5 µL of purified water to give a final 
reaction volume of 20 µL in a sterile microcentrifuge tube. The tube was placed in 
an incubator at 37˚C for 1.5 hours. Purified pET-28a was digested using the 
same enzymatic digestion protocol described above using 1µg of plasmid DNA. 
Both digestion products were purified using a 1% agarose gel made with 40 mM 
tris, 20 mM acetic acid, and 1 mM EDTA buffer (TAE buffer) at 90 V for 70 
minutes using a BioRad PowerPac Basic power supply and an Owl EasyCast 
B1A mini gel electrophoresis system (Thermo Scientific). Hi-Lo (Bionexus) and 
MassRuler Low Range (Thermo) DNA ladders were used for estimating DNA 
fragment sizes. All gels were imaged using the Fotodyne FOTO/Analyst PC 
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Image Version 5.00. Appropriate DNA bands were excised and purified from TAE 
gels using the QIAquick Gel Extraction Kit (Qiagen).  
Ligation was carried out using a 1:1 molar ratio of digested β1 DNA and 
digested pET-28a DNA. T4 DNA ligase (Thermo Scientific), along with the 
reaction buffer containing ATP, were used for DNA ligation and were allowed to 
react overnight at room temperature. The following morning 4 µL of the ligation 
reaction was combined with 25 µL of XL-10 Gold ultra-competent cells (Agilent). 
The cells were transformed and DNA was propagated and purified as described 
in section 4.2.1. The presence of the β1 gene was visually verified by digestion 
with NdeI and XhoI as described previously in the current section. DNA 
sequencing by UTHSC MRC was used to verify the sequence. 
4.2.3 Polymerase Chain Reaction Amplification of the β1 Gene 
DNA oligonucleotide primers were designed to amplify the β1 gene for 
ligation into pE-SUMOpro (Figure 27, Table 8). PCR242,243 was used to amplify 
the gene with the appropriate restriction endonuclease recognition sequences. 
The forward primer added a SfaNI (NEB) restriction site, while the reverse primer 
added an XhoI restriction site. The use of these two restriction sites added 
nucleotides to the β1 gene to produce complementary overhangs to the linearized 
form of pE-SUMOpro. This allowed for ligation of the gene into the vector. The 
Q5 High-Fidelity PCR Kit (NEB) was used to perform PCR reactions; 
manufacturer’s instructions were followed for reaction concentrations and PCR 
thermal cycling programs. The Eppendorf Mastercycler Personal machine was 
used to carry out all PCR reactions.  
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Table 8. PCR Primers for Ligation of the β1 Gene Into pE-SUMOpro  
The underlined sequences are the sequences of DNA overhangs from restriction 
enzyme cleavage sites needed for ligation into pE-SUMOpro linearized by BsaI. 
The forward primer contains an SfaNI cleavage site, while the reverse primer 
contains an XhoI cleavage site (shown in grey). 












The vector was prepared for ligation by linearizing with the restriction 
endonuclease BsaI (NEB). The β1 PCR product was prepared for ligation by 
digesting with SfaNI and XhoI and the ligation reaction, bacterial transformation, 
plasmid purification, and DNA sequence verification were carried out as 
described in section 4.2.2. 
4.2.4 Ligation Independent Cloning of β1 into pMCSG19 and 
pMCSG29 
The β1 gene was subcloned into pMCSG19 and pMCSG29225 (Figure 27) 
using ligation independent cloning techniques described in detail by Stolls et 
al.230 Bacterial transformation, plasmid purification, and sequence verification 
were performed as described in section 4.2.2. 
4.2.5 Expression Trials of β1 in pET-28a, pE-SUMOpro, pMCSG19, 
and pMCSG29 
Purified and sequence verified forms of all four vectors containing the β1 
gene were used to transform BL21 (DE3) and C43 (DE3)233 E. coli competent 
cells for protein expression. Starter cultures were prepared in a sterile 50 mL 
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centrifuge tube with 10 mL of sterile LB broth (Fisher), 1 µg/mL of the appropriate 
antibiotic, and a freshly isolated bacterial colony. The culture was grown 
overnight for no more than 16 hours in an incubator shaker at 37˚C and 250 rpm. 
The following morning, 50 mL of sterile LB broth were prepared with 1 µg/mL of 
antibiotic in a sterile 250 mL flask and warmed to 37˚C before adding 1 mL of the 
10 mL starter culture. The inoculated 250 mL flask was placed back in the 
incubator shaker at 37˚C and 250 rpm and the optical density (OD) was 
measured at 600 nm using an Agilent 8453 UV-Vis Spectrophotometer every 
hour until reaching an OD of 1.0. Protein expression was induced by the addition 
of isopropyl β-D-1-thiogalactopyranoside (IPTG) from a 1 M stock to a final 
concentration of 0.5 mM. Expression was carried out at 18˚C in some cases; 
cultures were grown as described, but switched to an 18˚C refrigerated shaker 
after induction of expression. A 1 mL sample of the bacterial culture was taken 
before inducing expression with IPTG and the sample was centrifuged at 
16,000xG to pellet cells. The supernatant was decanted and the cell pellet was 
stored at -20˚C. Additional samples were taken every hour or two hours and the 
number of cells in each sample was normalized using OD measurements. All 
samples were thawed at room temperature and re-suspended in 300 µL of lysis 
buffer (75 mM trizma base, 0.3 M NaCl, 0.2 mM EDTA to reduce proteolytic 
cleavage, and 10 μM butylated hyroxytoluene to act as a free-radical scavenger) 
with protease inhibitors. Roche complete protease inhibitor tablets were used and 
were prepared by dissolving one tablet in 50 mL of lysis buffer.  
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Cell lysis was accomplished using the Biologics Ultrasonic Homogenizer 
150 V/T with a titanium microtip. Sonicator power was set to 30% of maximum 
and a 50% pulse program (5 seconds on, 5 seconds off) was used for 3 minutes 
per sample with samples kept on ice. Whole cell protein samples were prepared 
by removing 25 μL of each sample into a sterile microcentrifuge tube and 25 μL 
of Laemmli sample buffer (BioRad, 65.8 mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% 
(w/v) glycerol, 0.01% bromophenol blue, 355 mM β-mercaptoethanol) was added 
to each tube. The remaining sonicated sample was then centrifuged at 16,000xG 
under refrigeration to 4˚C for 10 minutes to pellet insoluble cell debris. Cell lysate 
samples were prepared by pipetting 25 μL of the supernatant from the 
centrifuged samples and combining it with 25 μL of Laemmli sample buffer. Both 
sets of samples were placed on a rocker at room temperature for 30 minutes. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)244 was used to analyze expression time course samples. Fifteen µL of 
each time point’s whole cell and cell lysate samples were loaded into Mini-
Protean TGX AnykD 15 well precast gels (BioRad) along with Precision Plus 
Protein Kaleidoscope (BioRad) protein ladder. Tris/glycine/SDS running buffer 
(BioRad; 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) was added to the 
Mini-Protean Tetra Cell (BioRad) electrophoresis cell and all gels were run at 200 
V for 33 minutes. The gels were removed from cassettes and placed in a gel 
fixing solution containing 50% methanol and 10% acetic acid for 1 hour. The gels 
were then rinsed in water for 10 minutes and stained in Bio-Safe Coomasie 
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(BioRad) for one hour and de-stained in water for a minimum of one hour. All gels 
were imaged using the Fotodyne FOTO/Analyst PC Image Version 5.00.  
4.2.6 Large-Scale Expression of β1 in E. coli 
Large-scale expression of β1 protein was carried out in 4 L sterile flasks 
using 1 L of sterile LB broth. Fifty mL starter cultures were prepared as described 
in section 4.2.5 using pET-28a and pE-SUMOpro β1 constructs. Starter cultures 
were used to inoculate 1 L of sterile LB, which was pre-warmed to 37˚C in an 
incubator shaker. Cultures were grown to an OD of 1.0 before inducing protein 
expression by adding IPTG to a final concentration of 0.5 mM followed by 4 
hours incubation at 37˚C and 250 rpm. After 4 hours, the flasks were removed 
from the incubator shaker and placed on ice. Cells in the 1 L cultures were 
divided into 250 mL portions and pelleted by centrifuging in a Sorvall RC-5B 
refrigerated superspeed centrifuge with a GSA rotor at 5855xG for 30 minutes. 
Cell pellets that were not immediately used for purification were stored at -20˚C. 
4.2.7 Purification of β1 from Inclusion Bodies  
Frozen cell pellets from large-scale expression were removed from -20˚C 
storage and allowed to thaw at room temperature for 10 minutes. Pellets were re-
suspended in 20 mL of lysis buffer containing protease inhibitors and lysed as 
described in section 4.2.5. Centrifuging at 8800xG for 20 minutes pelleted cell 
debris, including protein inclusion bodies. The supernatant was discarded and 
the pellet was solubilized with 200 mL of lysis buffer + 0.5% SDS in a sterile 250 
mL flask in an incubator shaker at 37˚C. After one hour, the solution was 
centrifuged at 8800xG for 10 minutes to pellet any insoluble mass and the 
supernatant was transferred to a sterile flask. The supernatant was filtered using 
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a Millex GP 0.22 µm syringe-driven filter (Millipore) and a sterile syringe. Before 
solubilized protein was applied to the column, a loading sample was prepared by 
collecting 25 µL of solubilized protein and combining it with 25 µL of Laemmli 
buffer, as described in section 4.2.5. The filtered supernatant was applied to a 
HisTrap FF 5 mL Ni-NTA (GE Healthcare) IMAC column at a 5 mL/min flow rate 
using a Gilson MiniPuls3 peristaltic pump. An additional sample of the protein 
solution was taken after exposure to the column as described above and is 
referred to as the flow through sample. The loaded column was connected to the 
BioRad BioLogic LP chromatography system and all UV data was recorded using 
LP Data View MS Software Version 2.00 (BioRad). All purifications used a flow 
rate of 5 mL/min and UV data was recorded at 280 nm. 
To purify protein, the column was first treated with wash buffer (40 mM 
HEPES, 300 mM NaCl, 10 μM butylated hydroxytoluene, 0.5% SDS, pH 7.2) for 
10 minutes. On-column detergent exchange was carried out using rinse buffer 
(50 mM Na2HPO4, 300 mM NaCl, and 0.25% Fos-Choline-12, Sol-Grade (DPC, 
Affymetrix)) for 10 minutes. The purified protein was eluted from the column by 
washing the column with elution buffer (250 mM imidazole, 300 mM NaCl, 0.25% 
DPC or other detergents, pH 4) for 10 minutes. The pH of elution fractions was 
raised immediately after collection to 7.4 using 1 M Trizma base. Elution buffer 
was made using 0.25% SDS, 0.2% N-lauroylsarcosine (sarcosyl), or 0.2% 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (DHPC) in place of 0.2% DPC to elute 
the protein in different detergent micelles for later study. All fractions were 
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collected in 5 mL increments, one per minute, using the BioRad Model 2110 
fraction collector.  
Samples of each fraction were prepared by transferring 25 μL of each 
fraction to a sterile microcentrifuge tube and combining it with 25 μL of Laemmli 
buffer for analysis via SDS-PAGE, as described in section 4.2.5. Fractions 
containing purified protein were pooled and concentrated using Amicon Ultra-15 
centrifugal filter units with Ultracel-3 membrane (Millipore) by centrifuging at 
8800xG in 20 minute increments until the desired volume was obtained. The 
elution buffer was exchanged to phosphate buffered saline (PBS; 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4). Protein 
concentration was determined using the BCA Assay Kit (Thermo) following 
manufacturer’s instructions. Excel (Microsoft) was used for standard curve fitting 
of BCA assay data and concentration calculations. 
4.2.8 Binding Competition Assay of β1 Using Fluorescent Estradiol 
Fluorescently labeled BSA covalently linked to β-estradiol and fluorescein 
was used to measure binding of estradiol to β1 protein purified from E. coli. A 100 
µM stock of β-estradiol 6-(O-carboxy-methyl)oxime: BSA fluorescein 
iso-thiocyanate conjugate (BSA-E-F; Sigma, approximate molecular weight for lot 
purchased was 70,900)245 was prepared by dissolving 0.354 mg in 50 µL of 
purified water. A 1 mM stock of non-labeled estradiol was prepared by dissolving 
0.272 mg of estradiol in 1 mL of ethanol. Several serial dilutions were made 
(Table 9) to test 0.5, 1, 2, and 5 µM concentrations of BSA-E-F in the presence 
or absence of β-estradiol and β1 protein purified from BL21 (DE3) cells in 0.2% 
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SDS, DHPC, and sarcosyl detergent micelles (section 4.2.7). A 96-well His-select 
nickel coated plate (Sigma) was used to bind His tagged protein to the surface of 
the plate. Ethanol was added to solutions that did not contain β-estradiol, which 
was first dissolved in ethanol, to keep all solutions of equal composition. All 










F Added (μL) 







0 0 99.5 0.5 0 
0.5 0.5 99 0.5 0 
1 1 98.5 0.5 0 
2 2 97.5 0.5 0 
5 5 94.5 0.5 0 
5 5 94.5 0 0.5 




 Protein binding was accomplished by adding 200 µL of PBS containing 5 
µg/mL protein purified into detergent micelles to each well. The protein was 
allowed to incubate in the wells for 1 hour and the remaining solution was 
decanted. The wells were washed three times each with 300 µL of PBS 
containing the appropriate detergent. One hundred µL of each solution in Table 9 
was pipetted into each well in triplicate and allowed to incubate for one hour. Due 
to a low yield of protein purified in sarcosyl micelles, only the 5 µM 
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concentrations with and without β-estradiol were used. After incubation, the wells 
were washed three times with 300 µL of PBS containing the appropriate 
detergent. Fluorescence was measured at 521 nm with a 6 minute total run time 
taking fluorescence measurements every 2 minutes on a Synergy 2 plate reader 
(BioTek) and data was acquired on a computer running the Gen5 software 
package (BioTek). Blanks of 5 µM BSA-E-F with no protein and PBS only were 
used as controls, also in triplicate. The average and standard deviation of each 
detergent and BSA-E-F concentration combination were calculated using Excel 
(Microsoft). 
4.2.9 Surface Plasmon Resonance Binding Studies with Purified β1 
A nickel-coated surface plasmon resonance (SPR) chip was used to 
measure binding of β1 and ligands. The NiP SPR sensordisc (Xantec 
Bioanalytics) was cleaned with purified water and dried completely using nitrogen 
gas. The disk was loaded into the cell of the Autolab ESPRIT SPR instrument 
(Eco Chemie) and data was acquired on a computer running the accompanying 
Data Acquisition software version 4.2.2. The chip and cells were first rinsed with 
PBS in both channels before applying protein solution. Fifty µL of 5 µM solutions 
of purified protein were applied to both channels of the SPR cell and allowed to 
associate with the nickel-coated surface for 10 minutes with pump-controlled 
mixing. The cell was then washed again with PBS before adding 50 µL of a 5 µM 
solution of β-estradiol 6-(O-carboxy-methyl)oxime: BSA (BSA-E, Sigma) to one 
channel and 50 µL of a 5 µM solution of BSA (Thermo) to the other channel. The 
solutions were left in the cell for 10 minutes with mixing before being washed with 
PBS. Finally, 50 µL of 50 µM β-estradiol was loaded into each channel and 
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allowed to incubate with mixing for 10 minutes followed by a wash with PBS. 
Binding measurements were acquired throughout all solution applications and 
washes. 
4.2.10 Site Directed Mutagenesis of β1 for Cholane Binding Studies 
Custom DNA oligo primers were ordered from Operon to create a β1 
T169A mutant in the pET-28a construct. The sequences of the primers are 
shown in Table 10. Primers were reconstituted in purified water to a 
concentration of 100 µM. Mutagenesis was performed using a QuickChange 
Lightning Site-Directed Mutagenesis Kit (Agilent) and manufacturer instructions 
were followed. An Eppendorf Mastercycler Personal PCR machine was used to 
perform the reaction in duplicate following the manufacturer’s PCR thermal 
cycling sequence. The PCR products were transformed into XL1 Blue competent 
cells as described in section 4.2.2. Plasmid propagation, purification, and 
sequence verification were also performed as described in section 4.2.2. 
Expression trials and large-scale growth were performed as described in sections 
4.2.5 and 4.2.6, respectively. 
 
 
Table 10. Primers to Create β1 T169A Mutant 
Identifier DNA Sequence 
T169A Forward Primer CCTTTCTGCTGGCCGGTGGTCTGCT 









4.2.11 Binding Studies with Lithocholic Acid-Linked Magnetic Beads 
The synthesis of magnetic beads covalently linked to lithocholic acid 
(LCA) was completed by Lisa Chaney, an undergraduate student participating in 
the Research Experience for Undergraduates program in the summer of 2013. 
The unpublished synthesis is described for context.  
 BcMag Amine-Terminated beads (Bioclone) were rinsed with coupling 
buffer (10 mM K2HPO4, 0.15 M NaCl, pH 5.5) three times as instructed by the 
manufacturer. Supernatant was removed by placing microcentrifuge tubes 
containing the magnetic beads on the supplied magnetic separator and excess 
solution was decanted. The beads were resuspended in coupling buffer and 
combined with LCA solution (0.0346 g lithocholic acid (Sigma), 1.75 mL 
anhydrous 1,4-dioxane (Sigma), 0.75 mL purified water) and a coupling agent 
solution (0.0346g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, 25 mL purified 
water) and left at room temperature on a rocker. After 24 hours, the beads were 
rinsed with purified water and storage buffer (0.303 g tris base, 7.305 g NaCl, 
0.09 g EDTA, 0.25 g sodium azide, pH 6.99) three times. The beads were 
resuspended in storage buffer and stored at 4˚C until needed. 
For functional assessment, the magnetic separator supplied by the 
manufacturer was used to separate the beads and the storage buffer was 
decanted. The beads were washed three times with 1 mL of PBS and then 
resuspended in 2 mL of PBS. One mL aliquots of the PBS bead suspension were 
prepared in separate microcentrifuge tubes and 250 µL of 16 µg/mL WT β1 
protein was added to one and 250 µL of 16 µg/mL T169A β1 was added to the 
other. A control tube was prepared by combining 250 µL of 16 µg/mL WT β1 
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protein with unreacted magnetic beads. The tubes were placed on a rocker. After 
3 hours, the tubes were removed and the magnetic separator was used to 
separate the beads from the solution, which was decanted. The beads were then 
washed three times with PBS and 100 µL of 2x Laemmli buffer (BioRad) was 
added to each tube along with 100 µL of PBS to achieve 1x concentration of 
Laemmli. The tubes were inverted to mix and then placed on the rocker for 3 
minutes. The first elution sample (E1) was prepared by transferring 60 µL of the 
buffer to a new tube and the beads were placed back on the rocker overnight. 
The following morning a second elution sample (E2) was prepared in the same 
way and samples were analyzed using SDS-PAGE as described in section 4.2.5. 
4.3 Results and Discussion 
4.3.1 PCR and Vector Ligation 
After excision from the pMA-T vector received from GeneArt (Figure 29 A), 
the β1 gene was ligated into pET-28a. An enzymatic digestion of the pET-28a β1 
construct run on a 1% agarose TAE gel with the MassRuler DNA ladder showed 
the expected β1 DNA fragment at ~600 bp (Figure 29 B). Since the pET-28a 
construct including the His tag and β1 gene produces a 212 amino acid protein, 
the expected fragment is 636 bp and is in agreement with the agarose gel. Three 
DNA samples were purified from three separate colonies transformed using the 
ligation reaction of the β1 gene and pET-28a. All three DNA samples were 
digested, and showed a DNA fragment between the 500 bp and 750 bp markers 
in the Hi-Lo DNA ladder (Bionexus), visually confirming the presence of the β1 





Figure 29. pMA-T and pET-28a β1 Construct Digestion with NdeI and XhoI 
A) Double digestion of pMA-T vector containing the β1 gene. B) Double digestion 
of pET-28a vector containing the β1 gene. Three bacterial colonies were selected 





Agarose gel electrophoresis and DNA sequencing also confirmed PCR 
amplification of the β1 gene for LIC insertion into pMCSG19 and pMCSG29. The 
LIC method proved less reliable than traditional subcloning at first, so 20 colonies 
were selected after insertion of the β1 gene into pMCSG19 and purified by 
miniprep before digesting with NdeI and HindIII (New England Biolabs, Figure 30 
A). Due to the presence of the MBP fusion partner in both pMCSG19 and 
pMCSG29, the fragments are much larger than the fragments from pET-28a, 
which contains only a His tag and the β1 gene. DNA fragments containing the β1 
and MBP fusion partner gene from pMCSG19 were expected at ~2000 bp, while 
DNA fragments without the β1 gene were expected at ~1400 bp. The NEB Broad 




used Hi-Lo (Bionexus) due to availability issues. pMCSG29 was also digested 
(Figure 30 B), but XbaI and BamHI restriction enzymes (New England Biolabs) 





Figure 30. pMSCG19 and pMCSG29 β1 Construct Double Digest 
A) Double enzymatic digestion of the pMCSG19 β1 construct by NdeI and HindIII. 
Samples containing the β1 gene insert show bands at ~2000 bp, while samples 
without the insert show bands at ~1400 bp. Samples 3, 7, and 18 clearly showed 
presence of the β1 insert, while samples 4, 8, and 12 faintly show the insert and 
possible contamination from empty vector. B) All three miniprep samples 
digested with XbaI and BamHI showed the presence of the β1 insert while the 




In Figure 30 A, samples 3, 7, and 18 clearly show the presence of the β1 
insert, while samples 4, 8, and 12 show a faint band indicating the presence of 
the insert, but also show a band without insert. This could have been caused by 
collecting more than one bacterial colony from the agar plate during colony 
picking or could have been a result of uptake of more than one plasmid by the 
bacteria in the selected colony. These contaminated samples were not verified 
by sequencing, but the pure samples were used to confirm the presence of the β1 
insert. Figure 30 B shows the LIC method worked more reliably for pMCSG29 
with only three colonies being selected for digestion and all three miniprep 
samples containing the correct sequence, which was verified with DNA 
sequencing as described in section 4.2.2.  
The difference in success between LIC methods in pMCSG19 and 
pMCSG29 could be due to the difference in the nucleotides used in the LIC 
procedure described by Stols et al.230,225 pMCSG19 uses adenine and thymine 
base pairing to produce LIC overhangs in the DNA fragments, while pMCSG29 
uses guanine and cytosine base pairing. Commercially available kits from 
Novagen utilize the GC base pairing method used in pMCSG29, but no 
commercially available kits could be found utilizing the AT base pairing in 
pMCSG19. Problems also could have arisen from the use of 10 mM nucleotide 
stocks used with pMCSG19 vector and insert preparation, while 100 mM 
nucleotide stocks were used for pMCSG29. Glycerol and other stabilizing agents 
in the less concentrated stocks, which required larger volumes to complete the 
reactions, could have negatively impacted the function of T4 DNA polymerase, 
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interfering with the reaction necessary to produce complementary LIC overhangs 
on the vector and insert. 
4.3.2 Expressions of pET-28a, pE-SUMOpro, pMCSG19, and 
pMCSG29 β1 Constructs 
In this study, four bacterial expression vectors were used to determine the 
optimum expression plasmid for the β1 transmembrane protein in E. coli (Figure 
27). The first vector examined was pET-28a (Novagen), a basic E. coli 
expression plasmid containing a 6x-His tag for IMAC purification, a thrombin 
protease cleavage site, and the kanamycin antibiotic resistance gene for a 
selection marker. The second vector used was pE-SUMOpro Amp (LifeSensors), 
which contains a small ubiquitin-like modifier (SUMO) protein fusion partner for 
solubility enhancement232, a 6x-histidine tag for IMAC purification, and a SUMO 
Protease 2 cleavage site to remove the SUMO fusion protein after expression 
and purification. The SUMO vector also contains a gene for ampicillin antibiotic 
resistance as a selection marker. Both pET-28a and pE-SUMO use a multiple 
cloning site for gene insertion. 
The fusion protein in the pET-28a construct has a molecular weight of 25 
kiloDaltons (kDa), but appears in SDS-PAGE gels around 20 kDa caused by the 
hydrophobic nature of transmembrane segments binding more SDS than 
cytosolic proteins.246 pET-28a produced visible overexpression in the whole cell 
samples from BL21 cells at 18 and 37˚C (Figure 31 A, C, and D), but failed to 
show any protein in C43 cells at 37˚C (Figure 31 B), so 18˚C growth was not 
pursued. This construct is the favored construct for solution NMR, attributable to 
the lack of a large fusion partner that requires post-purification cleavage and 
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reduces protein yields. Samples labeled “L” in Figure 31 represent the lysate 
samples, while “W” samples represent whole cell samples whose collection and 
preparation were described in section 4.2.5. Since the protein being expressed is 
a membrane protein, it is not expected to express in lysate samples, which only 
contain soluble cytosolic proteins. Whole cell samples contain the cytosolic 
proteins, cell membranes, cell debris, and any protein aggregates or inclusion 
bodies. The stability of the protein expressed at 18˚C, which can clearly be seen 
through 48 hours of sampling, could indicate inclusion body formation. Trials 
using the pET-28a vector revealed that expression in the BL21 cell line was 
favored over C43 cells and that expression at 18˚C, which can improve 




Figure 31. Expression Trials of the pET-28a β1 Construct 
Samples labeled “L” represent the lysate samples, while “W” samples represent 
whole cell samples. Times displayed represent time passed since induction with 
IPTG. The Kaleidoscope protein standard was used for all gels and is denoted as 
“St” A) Expression in BL21 cells at 37˚C indicated overexpression at the 1 hour 
time point, which remained stable, and is evidenced by the band appearing 
around 20kDa. B) Expression in C43 cells showed minimal difference in the band 
at 20 kDa between pre and post-induction samples. C) Expression in BL21 cells 
at 18˚C first 8 hours of time points. Expression is visible after 2 hours, but is 
visibly overexpressed after 6 hours. D) Time points 22-48 hours after induction 




The SUMO-β1 fusion protein was expected at ~35 kDa if overexpression 
were observed owing to the presence of the 12-15 kDa SUMO fusion partner. 
Figure 32 shows the trial expression of the SUMO-β1 fusion in BL21 cells at 
37˚C. There was no discernable difference in expression levels for pre-induction 
0 hour time points compared to post-induction 2, 4, and 6 hour time points 
indicating there was no overexpression of protein for this construct, as evidenced 
by the lack of a band appearing in 2, 4, and 6 hour samples that is not also seen 
in the 0 hour samples. The pE-SUMOpro construct produced no overexpression 
of β1-SUMO fusion protein in BL21 or C43 cells in expression trials at 37˚C. 
Because of the lack of expression in both cell lines, the pE-SUMOpro construct 
was not pursued any further.  
 
 
Figure 32. Expression Trial of pE-SUMOpro β1 Construct 
Expression trials of SUMO-β1 fusion protein failed to show overexpression. The 





Expression from the pMCSG19 vector was much higher, as indicated by 
the large, dark band in Figure 33A in the 2 hour time point “W” sample between 
the 50 kDa and 75 kDa markers that does not appear in the 0 hour time point. 
The size of this band could be attributed to the large mass of MBP, which has a 
mass of 42 kDa, and not overall greater quantity of protein compared to the pET-
28a β1 expression profile. The presence of the band only in the whole cell sample 
could indicate protein aggregation, but could also be membrane embedded 
protein. The MBP fusion vectors, pMCSG19 and pMCSG29, both demonstrated 
overexpression only in C43 cells. pMCSG29 did not express as well as 
pMCSG19 and was not pursued any further due to the added complication of 
fusion partner cleavage after purification, but no added benefit of overexpression 




Figure 33. Expression Trials of pMCSG19 and pMCSG29 β1 Constructs 
A) pMCSG19 β1 expression in C43 cells indicated good overexpression of protein 
with a band around 60 kDa, but possibly as insoluble aggregates as was seen 
with pET-28a. B) pMCSG29 β1  expression did show overexpression, but not as 







After comparison of all expression trials, the pET-28a β1 construct was 
selected for large-scale expression and purification using IMAC. pET-28a was 
chosen over pMCSG19 for purification because they both showed expression in 
the whole cell fraction, but pET-28a does not require post-purification enzymatic 
digestion to remove a fusion partner. In pMCSG19, the large MBP fusion tag 
would require digestion to obtain a protein of suitable size for solution NMR study 
and the digestion step typically results in reduced yield due to additional 
purification steps required after digestion.  
4.3.3 Protein Purification and Solubilization in Detergent Micelles 
Four detergents were used for sample preparation: SDS, DPC, DHPC, 
and N-lauroylsarcosine (sarcosyl). All of these detergents produce micelles at or 
above concentrations of 0.2% m/v. These detergents offer various lipid head 
groups and alkyl chain lengths and were selected to provide a range of micelle 
environments to determine optimum conditions for β1 stabilization (Figure 34). 
SDS is an anionic detergent that can denature proteins in high concentration, but 
has allowed for quality NMR spectra collection for some proteins.247,248 Sarcosyl 
is also an anionic detergent, but is less commonly used. It has been used 
historically to solubilize membrane proteins,249 but has also been used to 
successfully stabilize membrane proteins.250 DPC and DHPC are both 
zwitterionic detergents and have both been used to characterize many 








Traditional IMAC purification without SDS in the lysis buffer requires a 
column wash containing 10-50 mM imidazole to remove weakly bound proteins 
before eluting the purified protein. However, with SDS in the lysis buffer, weak 
binding proteins did not readily adhere to the column. Recombinant β1 protein 
adhered beyond normal IMAC elution requirements of 250-500 mM imidazole 
after the on-column detergent exchange steps described in section 4.2.7. The 
elution buffer required a pH of 4 to remove protein from the column by 
protonating all histidine residues in the His tag, which have a pKa around 6.251 
The pH was immediately raised to 7.4 following elution to minimize structural 
issues caused by the low pH environment.252 Solubilization of the lysed cell pellet 
described in section 4.2.7 proved to be a very effective method to extract a large 
amount of protein with high purity (Figure 35), negating the need for a secondary 




Figure 35. SDS-PAGE Analysis of β1 Purification into DPC Micelles 
The lane labeled “St” is the protein standard for approximating molecular 
weights. “LS” is the load sample and “FT” is the flow through sample described in 
section 4.2.7. The numbers represent the fraction collected with the total number 
of fractions being 30. Fractions 1-10 are column wash fractions, 11-20 are 




The loading sample and flow through samples in Figure 35 show the 
solubilized protein, which appears around 20 kDa, was completely absorbed onto 
the IMAC column since it does not appear in the flow through sample taken after 
the solution was applied to the column. Column wash fractions 2 and 3 show that 
very little protein is weakly bound to the column. This is partly due to SDS 
interfering with binding of weakly attracted proteins and also due to the 
purification coming from the insoluble cell pellet and not the cell lysate, which 
contains most of the known contaminating proteins with IMAC affinity in E. coli.253 
The faint band that appears around 40 kDa is likely a dimerized aggregate of the 
solubilized protein. Samples without the band were concentrated separately and 
after concentration the band appeared in these samples as well. This could prove 
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to be a significant problem in any future NMR experiments since higher 
concentrations of protein are required and appearance of the dimer appears to 
be concentration dependent. This could possibly be avoided by using higher 
concentrations of detergent or carefully controlling the concentration to promote 
monodispersion of protein in micelles.254 Purification using IMAC led to 
successful purification and on-column detergent exchange into detergents other 
than SDS, which was used to solubilize protein initially. 
4.3.4 Functional Assessment of Purified β1 Protein 
Once purified, it must be determined if protein exhibits native-like 
behavior, and therefore proper folding, through functional studies. Since β1 had 
not been expressed in and purified from E. coli before, development of a 
functional assay proved to be a significant hurdle. With β1-specific ligands limited 
to hydrophobic compounds that readily partition into hydrophobic membrane 
protein-stabilizing environments,255 measuring the binding of ligands alone would 
not suffice, as non-specific binding of ligands would be high in the presence of 
detergent micelles. To deal with this problem several approaches were 
conceived, all of which center on β1 ligands covalently linked to larger 
macromolecules in an effort to reduce non-specific binding.  
 In the fluorescently labeled estradiol assay described in section 4.2.8, the 
average signals did appear to increase with increasing concentration of BSA-E-F; 
however, competition with unlabeled estradiol did not substantially diminish the 
signal.  Additionally, measurements from wells containing no fluorescein were 
3.5-4 standardized fluorescence units (SFU), about half of the total signal 
detected at the highest concentration of BSA-E-F indicating the signal-to-noise 
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ratio is very low(Table 11). This was likely due to the limited path length of the 
96-well plate since fluorescence measured by the plate reader was only coming 
from ligand bound to protein immobilized at the bottom of the nickel coated plate. 
With a very small path length, differences in fluorescence between samples were 
difficult to discern from background. Additionally, the estradiol could be 
partitioning into the membrane due to the hydrophobic nature of estradiol and the 
hydrophobic environment provided by the micelle preventing any competition 
with BSA-E-F. The fluorescently linked β-estradiol assay described in section 
4.2.8 failed to produce significant differences between samples with and without 




Table 11. β1 Fluorescein Assay Results 
Average and standard deviation calculations from BSA-E-F fluorescence assay 
of purified β1 protein incubated with fluorescently labeled BA conjugated to 
estradiol. Averages of fluorescence readings failed to show a significant 
difference between different concentrations of BSA-E-F. 
 SDS DHPC Sarcosyl 
 Average St Dev Average St Dev Average St Dev 
0 BSA-E 3.56 0.53 3.89 0.33   
0.5 µM BSA-E-F 7.00 0.71 7.67 1.22   
1 µM BSA-E-F 7.44 0.53 7.22 0.44   
2 µM BSA-E-F 8.00 0.50 7.44 0.53   
5 µM BSA-E-F 8.89 0.78 8.56 0.53 17.25 6.18 
5 µM BSA-E-F + 
5 µM Estradiol 8.67 1.00 12.5 5.59 8.33 1.15 




Since SPR can be used to detect protein interactions on the surface of the 
SPR chip,256 it was selected to study the interaction of β1 with ligands. However, 
since none of the β1 ligands have a mass large enough to detect with SPR, BSA 
covalently linked to estradiol was used to measure binding with BSA being used 
as a control. In theory, if the β1 protein were correctly folded, the BSA-E would 
bind and produce a measurable change on the surface of the SPR chip while the 
normal BSA would not. Addition of estradiol should displace the bound BSA-E 
while having no effect in the cell containing β1 and BSA.  
 Figure 36 shows the association of His tagged β1 with the Ni-NTA SPR 
chip. Even though equal amounts of protein solution were put in each channel, a 
difference of approximately 300 m˚ was detected between the two channels on 
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the SPR chip. This could be due to reuse of the chip causing degradation of the 
Ni-NTA surface. However, in Figure 37 after BSA and BSA-E are added, a mass 
change of ~300 m˚ was measured in channel 1 where BSA-E was added 
compared to BSA alone even though channel 1 contained a smaller amount of 
bound protein. Finally, in Figure 38 estradiol was added in 10-fold excess, but 
failed to show a significant difference in the mass lost between channel 1 and 
channel 2. Since channel 1 showed a larger mass gain when BSA-E was added, 
it was expected that the addition of estradiol would compete with BSA-E and the 
mass gain from Figure 37 would be measured as a mass loss in Figure 38. While 
the surface plasmon resonance experiments described in section 4.2.9 produced 
more promising results than the fluorescence assay, they still failed to show 








































































The failure to see a measurable mass change after addition of estradiol 
could be due to the BSA-E not binding to β1 on the surface of the chip and 
instead binding to micelles or interacting with the SPR chip surface.257 The data 
could also imply that the purified protein does not posses native structure since 
the ligand was unable to be removed through competition by estradiol. However, 
there could also be an issue with using estradiol for competition since the 
hydrophobic nature of the molecule will encourage it to partitioning into the 
detergent micelles present on the chip surface, which may be preferred over 
occupied ligand binding sites on β1. Additionally, since estradiol may require the 
presence of the α subunit for binding143, it may not be possible for binding to 
occur with this ligand. As a result of these issues, SPR and estradiol were 
abandoned as functional assessment tools.  
The final method used to assess functionality of β1 protein used a similar 
concept as the first two by covalently linking a known hydrophobic ligand to a 
large non-hydrophobic molecule. However, this method differed in that it used 
LCA linked to magnetic beads instead of estradiol linked to BSA. The cholane 
steroid-recognition site containing T169 is well characterized and has a known 
mutant (T169A) that does not exhibit the wild type LCA response in patch-clamp 
experiments using the T169A mutant.65 Because of a better understanding of 
LCA-β1 interaction and the use of a mutant as a negative control, this method 
was pursued to overcome the issues with using non-linked hydrophobic ligands 
suspected of partitioning into micelles.  
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In experiments with the magnetic beads covalently linked to LCA, both WT 
and T169A protein was bound to the beads by comparing the samples before 
exposure to the LCA beads (Sa) to samples after exposure to the LCA beads 
(Su) in Figure 39. Additionally, both WT and T169A proteins eluted in E1 and E2 
elution samples around 20kDa. While it is difficult to compare Sa and Su to E1 
and E2 due to differences in sample volumes and therefore concentrations of 
proteins in the samples, the Sa and Su samples from T169A in Figure 39 around 
the 20kDa marker show a greater uptake of β1 compared to other proteins in the 
sample. However, since there was no difference in protein bound to the beads in 
WT compared to T169A, this method also failed to demonstrate the functionality 
of β1 protein expressed in E. coli. The non-specific binding of both proteins could 
be due to LCA still interacting with the protein binding site or could be due to the 
same non-specific binding to micelles possibly encountered with the other two 
methods described previously. While the T169A mutant is known to not produce 
the wild type functional response to LCA,65 experimental data are not available 
regarding whether binding of LCA is altered in the mutant. This could help to 
explain the lack of difference in eluted protein in WT and T169A samples, but 
does not mitigate the fact that this assay also failed to demonstrate functionally 





Figure 39. Lithocholic Acid Magnetic Bead β1 Pull-down 
St represents the protein standard. Sa is the sample before exposure to 
magnetic beads. Su is the sample after exposure to magnetic beads. E1 and E2 
are the elution fractions as described in section 0. Control samples were 





While expression and purification protocols have been established by this 
study, a method to test the functionality of the protein expressed in E. coli 
remains elusive. This is, in part, due to the problems associated with all known β1 
ligands being hydrophobic molecules that will readily partition into any membrane 
or membrane-like environment rather than staying in an aqueous solution255. 
Unfortunately, without a method to adequately assess protein function, structural 
characterization of the protein with solution NMR was not justified at this time and 
resources involved in NMR experiments warrant evidence of native-like protein 
structure before experimentation begins. While these results did not demonstrate 
a difference between experimental samples and controls, this does not 
necessarily mean the methods themselves are incapable of assessing protein 
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function. If a well-dispersed heteronuclear spin quantum correlation (HSQC) 
NMR spectra can be obtained, experiments titrating known β1 ligands and 
observing changes in chemical shift would be sufficient to indicate proper 
structure and allow further NMR experiments to proceed. The problem could lie 
in the protein structure obtained from E. coli, which would necessitate different 
expression and purification protocols. Further experimentation with pMCSG19 β1 





Discussion, Conclusions, and Recommendations 
5.1 Discussion of Findings and Conclusions 
5.1.1 Molecular Dynamics Simulations of the BKCa α Subunit 
Cytosolic Domain 
The current molecular dynamics simulations have provided insight into the 
importance of specific residues in the stabilization of CLR on the CRAC4 domain 
in the BKCa α subunit cytosolic domain. Using simulated constructs that mimic 
experimental counterparts, variation in the behavior of CLR can be seen while 
interacting with CRAC4 residues of CTD, trCTD, and K453A and Y450F mutant 
constructs over 200 ns of simulation. With experimental results showing the 
trCTD construct is more sensitive than the full WT protein, the simulations 
provide evidence that the increased stability of CLR on CRAC4 in trCTD protein 
is caused, in part, by increased hydrogen bonding between K453 and CLR. Loss 
of this hydrogen bonding partner in K453A simulations resulted in a marked 
decrease in time CLR spent on CRAC4 residues 450 to 453 in triplicate 
simulations further supporting the idea that K453 is vital to the CLR sensitivity of 
the channel and explaining experimental data. However, two events in the 
simulations remain unexplained. First, the difference in the behavior of 
cholesterol between the trCTD and Y450F simulations, despite the presence of a 
hydrogen bonding partner, could be observed in simulation trajectories, but could 
not be explained quantitatively. Second, the migration of CLR to CRAC6 and 
CRAC7 in CTD simulations 1 and 2 remain unexplained by this study, although 
these two CRAC domains are both exposed and closer to CRAC4 than other 
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CTD CRAC motifs in the BKCa CTD model and crystal structure. While both of 
these likely have explanations in their respective simulation trajectories, limits on 
currently available analysis tools have prevented their description and 
quantification.  
5.1.2 Pharmacophore Modeling of the BKCa β1 Subunit 
By utilizing the knowledge gained from multiple generations of 
pharmacophore modeling and improvements in modeling software, there is now 
a robust tool that can be used to mine conformational databases to find new 
activators of BKCa channel activity. The 3rd generation model used in virtual 
screening has brought us closer to discovering therapeutic lead compounds that 
can be used to develop novel activators of BKCa through direct interactions with 
the β1 subunit. With tissue specific expression, targeting of the β1 subunit could 
provide new means of treating and managing diseases with a potentially smaller 
side effect profile than existing therapeutics. Additionally, using in vitro methods 
to test compounds discovered by virtual screening with these models will help to 
produce a new model that can strike a balance between sensitivity and specificity 
to provide significant enrichment of virtual screening results without discarding 
too many potentially active compounds. Since the current approach uses a 
model with high specificity, but low sensitivity, many compounds are being 
discarded in the initial search. A more balanced model would improve upon the 
search capabilities of the 3rd generation, as well as the combined 3rd and 6th 
generation model approach, by not discarding as many actives in the initial 
search. Furthermore, a more structurally diverse set of compounds that can be 
used to train or evaluate new models will provide a deeper understanding of the 
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cholane-steroid interaction site of the β1 subunit until high-resolution structural 
data are available.  
5.1.3 Expression and Purification of the BKCa β1 Subunit in E. coli 
With no high-resolution structural data available for any of the β subunits 
of the BKCa channel, developing and refining expression and purification 
protocols overcomes a major hurdle in the effort to obtain structural data. 
Successful expression of the β1 subunit in E. coli  was accomplished using 
optimization of the gene for the host organism and purification from insoluble cell 
mass was accomplished using IMAC purification techniques and on-column 
detergent exchange yielding highly pure protein samples stabilized in detergent 
micelles. Expression of the protein in E. coli provides the most cost-effective 
means to produce quantities of protein sufficient for NMR studies. However, 
before NMR structural studies can be carried out, proof of native-like activity 
must be obtained to justify the time and expense of NMR experiments. The 
methods described in this dissertation failed to show the reversible binding of 
known β1 subunit ligands, so structural studies are not yet justified. Since these 
experiments were not an exhaustive list of available options, the possibility 
remains that a method to demonstrate protein functionality is within reach and 
can provide the data necessary to commence structural studies via NMR. 
5.2 Recommendations for Future Research 
5.2.1 Understanding the Interactions Between Cholesterol and CRAC 
Motif Residues 
Although conclusions can be made about the importance of K453 in the 
BKCa CRAC4 motif, an explanation of the role for Y450 in cholesterol recognition 
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and stabilization remains unresolved. Further studies of the binding energies in 
this and other CRAC motifs using quantum mechanical methods may provide 
insight into the role each residue or the combination of residues plays in CLR 
recognition, but may be limited due to the computational time required to 
calculate larger atomic systems. Additionally, further simulations of a tetrameric 
assembly of CTD protein may provide results different from the current study due 
to the proximity of CRAC4 to the subunit interface in the tetrameric structure. 
With GPU acceleration of molecular dynamics simulations, a macromolecular 
simulation of this size is now feasible. Including a membrane-embedded CLR 
may also provide insight into the mechanism that causes CLR to leave the 
hydrophobic membrane environment to interact with cytosolic protein domains in 
BKCa α subunits, but these simulations may require an extensive time scale to 
produce an observable effect. More tractable simulations going forward could 
also include simulation of CLR starting on other CRAC motifs in the CTD protein 
structure to determine if the behavior of CLR observed on CRAC4 is unique. A 
few or all of these simulations would significantly further the knowledge of the 
interaction between CLR and BKCa. 
5.2.2 Improvements to Pharmacophore Models 
Armed with newly acquired compounds that will be confirmed to be either 
active or inactive using in vitro electrophysiology studies, improvements to the 
existing models or even entirely new models could be developed to improve 
upon the current understanding of the β1 subunit cholane-steroid recognition site 
pharmacophore. Increased structural diversity in compounds used to train 
models will provide new representations of the pharmacophore and hopefully 
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improve performance and produce a model that is more balanced between 
sensitivity and specificity and will not discard as many active compounds. With 
current models being overly discriminating or overly lax, a new model based on 
the most current and most active compounds could provide this more balanced 
approach. Furthermore, use of newer pharmacophore development tools, such 
as the ROCS software from OpenEye Scientific, could improve virtual screening 
methods by factoring molecular shape and volume into models along with ligand 
features similar to those used in MOE and discussed previously. Another 
software package of interest is the academically developed HPCC software,258 
which has proven as efficient as the commercially developed ROCS software in 
benchmarking tests. Using these new approaches, the discovery of therapeutic 
lead compounds to target the β1 subunit cholane-steroid recognition site would 
be accelerated and could lead to clinically relevant therapeutics in the long term. 
5.2.3 Functional Studies and Structural Characterization of the BKCa 
β1 Subunit 
Since the functional studies discussed in this dissertation did not show 
reversible binding of ligands, a new approach is needed to move forward with 
structural characterization. In many cases, a well-dispersed heteronuclear single 
quantum coherence (HSQC) spectrum is sufficient to indicate the existence of 
secondary structure in protein NMR, but this could be a significant challenge due 
to the helical nature of the β1 subunit. One option to overcome problems 
associated with overlapped chemical shifts in helical proteins would be to titrate a 
known β1 ligand into a protein sample in increasing concentrations to measure 
changes in chemical shift in an HSQC spectra. Due to the hydrophobic nature of 
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the known β1 ligands and the presence of detergent micelles, functional assays 
have proven fruitless, but this method should produce changes in chemical shifts 
only in residues associated with binding in the cholane-steroid recognition site. 
Thus non-specific interactions which would have more global impact on protein 
chemical shifts could be differentiated from specific interactions without the need 
to displace a hydrophobic ligand from both the protein surface and the micelle. 
If well-ordered secondary structure and ligand binding are not observed in 
HSQC experiments, varying the purification protocol to include more mild 
detergents may produce higher quality, but less pure protein. Some more recent 
methods include gentle sonication of insoluble cell mass to quickly solubilize 
proteins without the use of denaturing conditions or harsh detergents. Since SDS 
interferes with IMAC binding, changing the solubilization detergent would 
probably yield a less pure sample that would have to undergo a secondary 
purification step, for which a protocol would have to be developed. However, if 
less harsh detergent conditions produce a higher quality, properly folded sample 
that can lead to structural studies, any loss of protein in secondary purification 
would be justifiable to eventually produce high-resolution structural data.  
Recent advancements in the structural characterization of membrane 
proteins by solution NMR should provide high quality data that will lead to protein 
structure. An alternative would be the use of solid state NMR of proteins 
imbedded in membrane patches if solution NMR techniques fail. For an extensive 
discussion of membrane mimetics for solution NMR see Warschawski et al259 
and for a review of integral membrane proteins studied using NMR see Kang et 
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al.222 With the refined protocol for expression and purification of β1 protein in E. 
coli described in this dissertation, obtaining high resolution structural data for the 
subunit, which would provide invaluable insight into structure and also assist in 
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Appendix A: DNA and Protein Sequence of E. Coli Optimized β1 
CAT ATG ATG GGC AAA AAA CTG GTT ATG GCA CAG AAA CGT GGT GAA 
H M M G K K L V M A Q K R G E 
ACC CGT GCA CTG TGT CTG GGT GTT GCA ATG GTT GTT TGT GCA GCA 
T R A L C L G V A M V V C A A 
ATT ACC TAT TAT ATC CTG GGC ACC ACC GTT CTG CCG CTG TAT CAG 
I T Y Y I L G T T V L P L Q K 
AAA AGC GTT TGG ACC CAA GAA AGC ACC TGT CTG CTG GTT GAA ACC 
K S V W T Q E S T C L L V E T 
AAC ATT AAA GAT CAA GAA GAA CTG GAA GGT CGT AAA GTT CCG CAG 
N I K D Q E E L E G R K V P Q 
TAT CCG TGT CTG TGG GTT AAT GTT AGC GCA GTT GGT CGT TGG GCA 
Y P C L W V N V S A V G R W A 
ATG CTG TAT CAT ACC GAA GAT ACC CGT GAT CAG AAT CAG CAG TGT 
M L Y H T E D T R D Q N Q Q C 
AGC TAT ATT CCG CGT AAT CTG GAT AAC TAT CAG ACC GCA CTG GTT 
S Y I P R N L D N Y Q T A L V 
GAT GTT AAA AAA GTT CGT GCC AAC TTC TAC AAA CAC CAC AAC TTT 
D V K K V R A N F Y K H H N F 
TAT TGT TTT AGC GCA CCG CAG GTT AAT GAA ACC AGC GTT GTT TAT 
T C F S A P Q V N E T S V V Y 
CAG CGT CTG TAT GGT CCG CAG ATT CTG CTG TTT AGC TTT TTT TGG 
Q R L Y G P Q I L L F S F F W 
CCG ACC TTT CTG CTG ACC GGT GGT CTG CTG ATT ATT GCC ATG GTT 
P T F L L T G G L L I I A M V 
AAA CTG AAT CGT AGC CTG AGC GTT CTG GCA GCA CAG AAA TAA CTC 
K L N R S L S V L A A Q K Stop L 
GAG               
E               
 
